2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gibbons, 2013, The next steps in developing clinical practice guidelines for prevention, J Am Coll Cardiol, 62, 1399, 10.1016/j.jacc.2013.08.004
Gibbons, 2013, Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute, J Am Coll Cardiol, 62, 1396, 10.1016/j.jacc.2013.08.003
2011
2011
Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2304, 10.1016/j.jacc.2014.03.016
ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association, 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed September 15, 2017.
Halperin, 2016, Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 67, 1572, 10.1016/j.jacc.2015.09.001
Jacobs, 2013, ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 61, 213, 10.1016/j.jacc.2012.09.025
Jacobs, 2014, The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 64, 1373, 10.1016/j.jacc.2014.06.001
1959, Vol 1
Dawber, 1980
1967, Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg, JAMA, 202, 1028, 10.1001/jama.1967.03130240070013
1970, Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg, JAMA, 213, 1143, 10.1001/jama.1970.03170330025003
1977, Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study, JAMA, 237, 255, 10.1001/jama.1977.03270300059008
Moser, 2013, The treatment of hypertension: a remarkable success story, J Clin Hypertens (Greenwich), 15, 88, 10.1111/jch.12033
Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019
Gerhard-Herman, 2017, 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 69, e71, 10.1016/j.jacc.2016.11.007
Funder, 2016, The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 101, 1889, 10.1210/jc.2015-4061
Lenders, 2014, Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 1915, 10.1210/jc.2014-1498
January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, 64, e1, 10.1016/j.jacc.2014.03.022
Nishimura, 2017, 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 135, e1159, 10.1161/CIR.0000000000000503
Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2935, 10.1016/j.jacc.2013.11.005
2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2960, 10.1016/j.jacc.2013.11.003
Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151
Jensen, 2014, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, Circulation, 129, S102, 10.1161/01.cir.0000437739.71477.ee
O'Gara, 2013, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 61, e78, 10.1016/j.jacc.2012.11.019
Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002
Regitz-Zagrosek, 2011, ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC), Eur Heart J, 32, 3147, 10.1093/eurheartj/ehr218
Mosca, 2011, Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association, Circulation, 123, 1243, 10.1161/CIR.0b013e31820faaf8
Greenland, 2010, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 56, e50, 10.1016/j.jacc.2010.09.001
2004, The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents, Pediatrics, 114, 555, 10.1542/peds.114.2.S2.555
Elijovich, 2016, Salt sensitivity of blood pressure: a scientific statement from the American Heart Association, Hypertension, 68, e7, 10.1161/HYP.0000000000000047
Brush, 2015, 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers, J Am Coll Cardiol, 65, 2118, 10.1016/j.jacc.2015.03.550
Rosendorff, 2015, Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension, J Am Coll Cardiol, 65, 1998, 10.1016/j.jacc.2015.02.038
Flynn, 2014, Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association, Hypertension, 63, 1116, 10.1161/HYP.0000000000000007
Go, 2014, An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention, Hypertension, 63, 878, 10.1161/HYP.0000000000000003
O'Brien, 2013, European Society of Hypertension position paper on ambulatory blood pressure monitoring, J Hypertens, 31, 1731, 10.1097/HJH.0b013e328363e964
Artinian, 2010, Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association, Circulation, 122, 406, 10.1161/CIR.0b013e3181e8edf1
Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment:a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141
Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8
Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1
Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8
Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1
Rutan, 1988, Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial, Circulation, 77, 504, 10.1161/01.CIR.77.3.504
Sesso, 2000, Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men, Hypertension, 36, 801, 10.1161/01.HYP.36.5.801
Stamler, 1993, Blood pressure, systolic and diastolic, and cardiovascular risks. US population data, Arch Intern Med, 153, 598, 10.1001/archinte.1993.00410050036006
Benetos, 2002, Prognostic value of systolic and diastolic blood pressure in treated hypertensive men, Arch Intern Med, 162, 577, 10.1001/archinte.162.5.577
Lindenstrom, 1995, Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study, Am J. Epidemiol, 142, 1279, 10.1093/oxfordjournals.aje.a117595
Zhao, 2014, Brachial pulse pressure and cardiovascular or all-cause mortality in the general population: a meta-analysis of prospective observational studies, J Clin Hypertens (Greenwich), 16, 678, 10.1111/jch.12375
Mosley, 2007, Predictive utility of pulse pressure and other blood pressure measures for cardiovascular outcomes, Hypertension, 49, 1256, 10.1161/HYPERTENSIONAHA.106.083592
Franklin, 2009, Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study, Circulation, 119, 243, 10.1161/CIRCULATIONAHA.108.797936
Kodama, 2014, Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus, Am J Cardiol, 113, 1058, 10.1016/j.amjcard.2013.12.005
Lim, 2012, A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2224, 10.1016/S0140-6736(12)61766-8
Forouzanfar, 2017, Global burden of hypertension and systolic blood pressure of at Least 110 to 115 mm Hg, 1990-2015, JAMA, 317, 165, 10.1001/jama.2016.19043
Danaei, 2009, The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors, PLoS Med, 6, 10.1371/journal.pmed.1000058
Ford, 2011, Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States, Circulation, 123, 1737, 10.1161/CIRCULATIONAHA.110.005645
Cheng, 2014, Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study, Circulation, 130, 820, 10.1161/CIRCULATIONAHA.113.008506
Willey, 2014, Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study, J Am Heart Assoc., 3
Saran, 2015, US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States, Am J Kidney Dis, 66 Svii, S1
Wilson, 1999, Clustering of metabolic factors and coronary heart disease, Arch Intern Med, 159, 1104, 10.1001/archinte.159.10.1104
Berry, 2012, Lifetime risks of cardiovascular disease, N Engl J Med, 366, 321, 10.1056/NEJMoa1012848
Egan, 2014, Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals, Circulation, 130, 1692, 10.1161/CIRCULATIONAHA.114.010676
2014
Muntner, 2010, Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study, Am J Kidney Dis, 55, 441, 10.1053/j.ajkd.2009.09.014
Tanner, 2013, Prevalence of apparent treatment-resistant hypertension among individuals with CKD, Clin J Am Soc Nephrol, 8, 1583, 10.2215/CJN.00550113
Saydah, 2014, Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999-2010, Obesity (Silver Spring), 22, 1888, 10.1002/oby.20761
Castelli, 1984, Epidemiology of coronary heart disease: the Framingham study, Am J Med, 76, 4, 10.1016/0002-9343(84)90952-5
Sarzani, 2008, Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans, J Hypertens, 26, 831, 10.1097/HJH.0b013e3282f624a0
Grassi, 1995, Sympathetic activation in obese normotensive subjects, Hypertension, 25, 560, 10.1161/01.HYP.25.4.560
Kim, 2006, Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms, Circulation, 113, 1888, 10.1161/CIRCULATIONAHA.105.563213
McEvoy, 2016, CPAP for prevention of cardiovascular events in obstructive sleep apnea, N Engl J Med, 375, 919, 10.1056/NEJMoa1606599
Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8
Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1
Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8
Guo, 2013, Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies, Curr Hypertens Rep, 15, 703, 10.1007/s11906-013-0403-y
Guo, 2013, Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies, PLoS ONE, 8
Huang, 2014, Prehypertension and the risk of stroke: a meta-analysis, Neurology, 82, 1153, 10.1212/WNL.0000000000000268
Huang, 2015, Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta-analysis, J Am Heart Assoc., 4
Huang, 2014, Prehypertension and incidence of ESRD: a systematic review and meta-analysis, Am J Kidney Dis, 63, 76, 10.1053/j.ajkd.2013.07.024
Huang, 2014, Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis, Am Heart J, 167, 160, 10.1016/j.ahj.2013.10.023
Huang, 2013, Prehypertension and incidence of cardiovascular disease: a meta-analysis, BMC Med, 11, 177, 10.1186/1741-7015-11-177
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Lee, 2011, Presence of baseline prehypertension and risk of incident stroke: a meta-analysis, Neurology, 77, 1330, 10.1212/WNL.0b013e3182315234
Shen, 2013, Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease, Am J Cardiol, 112, 266, 10.1016/j.amjcard.2013.03.023
Sundstrom, 2015, Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis, Ann Intern Med, 162, 184, 10.7326/M14-0773
Thomopoulos, 2014, Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials, J Hypertens, 32, 2296, 10.1097/HJH.0000000000000379
Wang, 2013, Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies, Int J Cardiol, 168, 4857, 10.1016/j.ijcard.2013.07.063
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Cushman, 2002, Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), J Clin Hypertens (Greenwich), 4, 393, 10.1111/j.1524-6175.2002.02045.x
Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3
Wald, 2009, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials, Am J Med, 122, 290, 10.1016/j.amjmed.2008.09.038
Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
Yoon, 2015, Trends in blood pressure among adults with hypertension: United States, 2003 to 2012, Hypertension, 65, 54, 10.1161/HYPERTENSIONAHA.114.04012
Muntner, 2010, Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis, Hypertension, 55, 1339, 10.1161/HYPERTENSIONAHA.109.149609
Parikh, 2008, A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study, Ann Intern Med, 148, 102, 10.7326/0003-4819-148-2-200801150-00005
Carson, 2011, Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis, Hypertension, 57, 1101, 10.1161/HYPERTENSIONAHA.110.168005
Vasan, 2002, Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study, JAMA, 287, 1003, 10.1001/jama.287.8.1003
Shihab, 2012, Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study, Circulation, 126, 2983, 10.1161/CIRCULATIONAHA.112.117333
Whelton, 2015, The elusiveness of population-wide high blood pressure control, Annu Rev Public Health, 36, 109, 10.1146/annurev-publhealth-031914-122949
Crim, 2012, National surveillance definitions for hypertension prevalence and control among adults, Circ Cardiovasc Qual Outcomes, 5, 343, 10.1161/CIRCOUTCOMES.111.963439
Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
1977, Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study, JAMA, 237, 255, 10.1001/jama.1977.03270300059008
1993, The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V), Arch Intern Med, 153, 154, 10.1001/archinte.1993.00410020010002
Burt, 1995, Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991, Hypertension, 25, 305, 10.1161/01.HYP.25.3.305
Gee, 2014, Standards for the uniform reporting of hypertension in adults using population survey data: recommendations from the World Hypertension League Expert Committee, J Clin Hypertens (Greenwich), 16, 773, 10.1111/jch.12387
Burt, 1995, Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991, Hypertension, 26, 60, 10.1161/01.HYP.26.1.60
Hajjar, 2003, Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000, JAMA, 290, 199, 10.1001/jama.290.2.199
Egan, 2014, Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals, Circulation, 130, 1692, 10.1161/CIRCULATIONAHA.114.010676
Nwankwo, 2013, Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012, NCHS Data Brief, 1
2014
Bromfield, 2014, Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010, J Clin Hypertens (Greenwich), 16, 270, 10.1111/jch.12281
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981
Williamson, 2016, Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial, JAMA, 315, 2673, 10.1001/jama.2016.7050
Fletcher, 2012, Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository, Circulation, 125, 2462, 10.1161/CIRCULATIONAHA.111.029983
Jaffe, 2013, Improved blood pressure control associated with a large-scale hypertension program, JAMA, 310, 699, 10.1001/jama.2013.108769
Jaffe, 2016, The Kaiser Permanente Northern California story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013), J Clin Hypertens (Greenwich), 18, 260, 10.1111/jch.12803
Leung, 2017, Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults, Can J Cardiol, 33, 557, 10.1016/j.cjca.2017.03.005
Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151
Weir, 2014, In the clinic: hypertension, Ann Intern Med, 161, ITC1, 10.7326/0003-4819-161-11-201412020-01006
Liu, 2016, Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement, Blood Press Monit., 21, 178, 10.1097/MBP.0000000000000175
Kantola, 2005, Bell or diaphragm in the measurement of blood pressure?, J Hypertens, 23, 499, 10.1097/01.hjh.0000160204.74028.95
Uhlig, 2012
Margolis, 2013, Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial, JAMA, 310, 46, 10.1001/jama.2013.6549
McManus, 2014, Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial, JAMA, 312, 799, 10.1001/jama.2014.10057
Siu, 2015, Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 163, 778, 10.7326/M15-2223
Yi, 2015, Self-blood pressure monitoring in an urban, ethnically diverse population: a randomized clinical trial utilizing the electronic health record, Circ Cardiovasc Qual Outcomes, 8, 138, 10.1161/CIRCOUTCOMES.114.000950
Agarwal, 2011, Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis, Hypertension, 57, 29, 10.1161/HYPERTENSIONAHA.110.160911
O'Brien, 2017, The pursuit of accurate blood pressure measurement: a 35-year travail, J Clin Hypertens (Greenwich), 19, 746, 10.1111/jch.13005
Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151
Pickering, 2008, Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association, Hypertension, 52, 10, 10.1161/HYPERTENSIONAHA.107.189010
2011
Pickering, 2006, Ambulatory blood-pressure monitoring, N Engl J Med, 354, 2368, 10.1056/NEJMra060433
Tunis SR. Decision Memo for Ambulatory Blood Pressure Monitoring (CAG-00067N). Centers for Medicare and Medicaid Services; October 17, 2001.
Shimbo, 2014, The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010, J Am Soc Hypertens, 8, 891, 10.1016/j.jash.2014.09.015
Kent, 2014, Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries, J Am Soc Hypertens, 8, 898, 10.1016/j.jash.2014.09.020
Dabl Educational Trust. Information on validated blood pressure devices and monitors. Available at: http://www.dableducational.org. Accessed September 17, 2017.
British Hypertension Society. BP Monitors. Available at: http://www.bhsoc.org/bp-monitors/bp-monitors. Accessed September 17, 2017.
Pickering, 2008, ASH position paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring, J Clin Hypertens (Greenwich), 10, 850, 10.1111/j.1751-7176.2008.00043.x
O'Brien, 2013, European Society of Hypertension position paper on ambulatory blood pressure monitoring, J Hypertens, 31, 1731, 10.1097/HJH.0b013e328363e964
Kikuya, 2007, Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk, Circulation, 115, 2145, 10.1161/CIRCULATIONAHA.106.662254
Niiranen, 2013, Outcome-driven thresholds for home blood pressure measurement: international database of home blood pressure in relation to cardiovascular outcome, Hypertension, 61, 27, 10.1161/HYPERTENSIONAHA.111.00100
Head, 2010, Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study, BMJ, 340, c1104, 10.1136/bmj.c1104
Hansen, 2008, Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications, J Clin Hypertens (Greenwich), 10, 377, 10.1111/j.1751-7176.2008.07681.x
Ravenell, 2017, Thresholds for ambulatory blood pressure among African Americans in the Jackson Heart Study, Circulation, 135, 2470, 10.1161/CIRCULATIONAHA.116.027051
Hansen, 2007, Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals, J Hypertens, 25, 1554, 10.1097/HJH.0b013e3281c49da5
Roush, 2014, Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension, J Hypertens, 32, 2332, 10.1097/HJH.0000000000000355
Mancia, 2009, Long-term risk of sustained hypertension in white-coat or masked hypertension, Hypertension, 54, 226, 10.1161/HYPERTENSIONAHA.109.129882
Ben-Dov, 2007, Reproducibility of white-coat and masked hypertension in ambulatory BP monitoring, Int J Cardiol, 117, 355, 10.1016/j.ijcard.2006.04.088
Bidlingmeyer, 1996, Isolated office hypertension: a prehypertensive state?, J Hypertens, 14, 327, 10.1097/00004872-199603000-00009
Muxfeldt, 2012, Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension, Hypertension, 59, 384, 10.1161/HYPERTENSIONAHA.111.185405
Palatini, 2004, Prevalence and clinical significance of isolated ambulatory hypertension in young subjects screened for stage 1 hypertension, Hypertension, 44, 170, 10.1161/01.HYP.0000135250.57004.19
Trudel, 2013, Persistence and progression of masked hypertension: a 5-year prospective study, Int J Hypertens, 2013, 836387, 10.1155/2013/836387
Ugajin, 2005, White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study, Arch Intern Med, 165, 1541, 10.1001/archinte.165.13.1541
Pickering, 1988, How common is white coat hypertension?, JAMA, 259, 225, 10.1001/jama.1988.03720020027031
Piper, 2015, Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med, 162, 192, 10.7326/M14-1539
Ohkubo, 2005, Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study, J Am Coll Cardiol, 46, 508, 10.1016/j.jacc.2005.03.070
Fagard, 2007, Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis, J Hypertens, 25, 2193, 10.1097/HJH.0b013e3282ef6185
2011
Asayama, 2014, Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population, Hypertension, 64, 935, 10.1161/HYPERTENSIONAHA.114.03614
Mancia, 2013, Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements, Hypertension, 62, 168, 10.1161/HYPERTENSIONAHA.111.00690
Pierdomenico, 2011, Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis, Am J Hypertens, 24, 52, 10.1038/ajh.2010.203
Viera, 2010, Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring, Am J Hypertens, 23, 1190, 10.1038/ajh.2010.158
Viera, 2014, Reproducibility of masked hypertension among adults 30 years or older, Blood Press Monit., 19, 208, 10.1097/MBP.0000000000000054
Stergiou, 2014, Prognosis of white-coat and masked hypertension: International Database of Home Blood Pressure in Relation to Cardiovascular Outcome, Hypertension, 63, 675, 10.1161/HYPERTENSIONAHA.113.02741
Tomiyama, 2006, Masked hypertension and target organ damage in treated hypertensive patients, Am J Hypertens, 19, 880, 10.1016/j.amjhyper.2006.03.006
Perloff, 1983, The prognostic value of ambulatory blood pressures, JAMA, 249, 2792, 10.1001/jama.1983.03330440030027
Banegas, 2014, High prevalence of masked uncontrolled hypertension in people with treated hypertension, Eur Heart J, 35, 3304, 10.1093/eurheartj/ehu016
Gorostidi, 2015, Prevalence of white-coat and masked hypertension in national and international registries, Hypertens Res., 38, 1, 10.1038/hr.2014.149
Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141
O'Brien, 2013, European Society of Hypertension position paper on ambulatory blood pressure monitoring, J Hypertens, 31, 1731, 10.1097/HJH.0b013e328363e964
Wang, 2017, Prevalence of masked hypertension among US Adults with nonelevated clinic blood pressure, Am J Epidemiol, 185, 194
Peacock, 2014, Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions, J Hum Hypertens, 28, 521, 10.1038/jhh.2014.9
Conen, 2014, Age-specific differences between conventional and ambulatory daytime blood pressure values, Hypertension, 64, 1073, 10.1161/HYPERTENSIONAHA.114.03957
Alwan, 2014, Epidemiology of masked and white-coat hypertension: the family-based SKIPOGH study, PLoS ONE, 9, 10.1371/journal.pone.0092522
Shimbo, 2012, Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study, Am J Hypertens, 25, 664, 10.1038/ajh.2012.15
Franklin, 2016, The cardiovascular risk of white–coat hypertension, J Am Coll Cardiol, 68, 2033, 10.1016/j.jacc.2016.08.035
Tientcheu, 2015, Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study, J Am Coll Cardiol, 66, 2159, 10.1016/j.jacc.2015.09.007
Briasoulis, 2016, White-coat hypertension and cardiovascular events: a meta-analysis, J Hypertens, 34, 593, 10.1097/HJH.0000000000000832
Siu, 2015, Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 163, 778, 10.7326/M15-2223
Bayo, 2006, Home blood pressure self-monitoring: diagnostic performance in white-coat hypertension, Blood Press Monit., 11, 47, 10.1097/01.mbp.0000200479.19046.94
Nasothimiou, 2012, Diagnostic accuracy of home vs. ambulatory blood pressure monitoring in untreated and treated hypertension, Hypertens Res., 35, 750, 10.1038/hr.2012.19
Sega, 2001, Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study), Circulation, 104, 1385, 10.1161/hc3701.096100
Hansen, 2007, Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals, J Hypertens, 25, 1554, 10.1097/HJH.0b013e3281c49da5
Diaz, 2015, Prevalence, determinants, and clinical significance of masked hypertension in a population-based sample of African Americans: the Jackson Heart Study, Am J Hypertens, 28, 900, 10.1093/ajh/hpu241
Andalib, 2012, Determinants of masked hypertension in hypertensive patients treated in a primary care setting, Intern Med J, 42, 260, 10.1111/j.1445-5994.2010.02407.x
Terawaki, 2008, Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population: the Ohasama study, Hypertens Res., 31, 2129, 10.1291/hypres.31.2129
Kaplan, 2006, Primary hypertension: pathogenesis, 50
Padmanabhan, 2015, Genetic and molecular aspects of hypertension, Circ Res., 116, 937, 10.1161/CIRCRESAHA.116.303647
Lifton, 2001, Molecular mechanisms of human hypertension, Cell., 104, 545, 10.1016/S0092-8674(01)00241-0
Ference, 2014, Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension, Hypertension, 63, 1182, 10.1161/HYPERTENSIONAHA.113.02734
Savica, 2010, The effect of nutrition on blood pressure, Annu Rev Nutr, 30, 365, 10.1146/annurev-nutr-010510-103954
Chan, 2016, An update on nutrients and blood pressure, J Atheroscler Thromb, 23, 276, 10.5551/jat.30000
Tang, 2017, Gut microbiota in cardiovascular health and disease, Circ Res., 120, 1183, 10.1161/CIRCRESAHA.117.309715
Harsha, 2008, Weight loss and blood pressure control (Pro), Hypertension, 51, 1420, 10.1161/HYPERTENSIONAHA.107.094011
Hubert, 1983, Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study, Circulation, 67, 968, 10.1161/01.CIR.67.5.968
Huang, 1998, Body weight, weight change, and risk for hypertension in women, Ann Intern Med, 128, 81, 10.7326/0003-4819-128-2-199801150-00001
Hall, 2003, The kidney, hypertension, and obesity, Hypertension, 41, 625, 10.1161/01.HYP.0000052314.95497.78
Jones, 1994, Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey, J Hypertens, 12, 1433, 10.1097/00004872-199412000-00018
Mertens, 2000, Overweight, obesity, and blood pressure: the effects of modest weight reduction, Obes Res., 8, 270, 10.1038/oby.2000.32
Garrison, 1987, Incidence and precursors of hypertension in young adults: the Framingham Offspring Study, Prev Med, 16, 235, 10.1016/0091-7435(87)90087-9
Forman, 2009, Diet and lifestyle risk factors associated with incident hypertension in women, JAMA, 302, 401, 10.1001/jama.2009.1060
Juonala, 2011, Childhood adiposity, adult adiposity, and cardiovascular risk factors, N Engl J Med, 365, 1876, 10.1056/NEJMoa1010112
Klag, 1995, The contribution of urinary cations to the blood pressure differences associated with migration, Am J Epidemiol, 142, 295, 10.1093/oxfordjournals.aje.a117635
1988, Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group, BMJ, 297, 319, 10.1136/bmj.297.6644.319
Mente, 2014, Association of urinary sodium and potassium excretion with blood pressure, N Engl J Med, 371, 601, 10.1056/NEJMoa1311989
Elliott, 1996, Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group, BMJ, 312, 1249, 10.1136/bmj.312.7041.1249
Takase, 2015, Dietary sodium consumption predicts future blood pressure and incident hypertension in the Japanese normotensive general population, J Am Heart Assoc., 4
Stamler, 1997, The INTERSALT study: background, methods, findings, and implications, Am J Clin Nutr, 65, 626S, 10.1093/ajcn/65.2.626S
Strazzullo, 2009, Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies, BMJ, 339, b4567, 10.1136/bmj.b4567
Whelton, 2014, Sodium, potassium, blood pressure, and cardiovascular disease in humans, Curr Hypertens Rep, 16, 465, 10.1007/s11906-014-0465-5
Whelton, 2012, Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations, Circulation, 126, 2880, 10.1161/CIR.0b013e318279acbf
2005
Weinberger, 1986, Definitions and characteristics of sodium sensitivity and blood pressure resistance, Hypertension, 8, II127, 10.1161/01.HYP.8.6_Pt_2.II127
Sanada, 2011, Genetics of salt-sensitive hypertension, Curr Hypertens Rep, 13, 55, 10.1007/s11906-010-0167-6
Carey, 2012, Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter, Hypertension, 60, 1359, 10.1161/HYPERTENSIONAHA.112.196071
Elijovich, 2016, Salt sensitivity of blood pressure: a scientific statement from the American Heart Association, Hypertension, 68, e7, 10.1161/HYP.0000000000000047
Weinberger, 1996, Salt sensitivity of blood pressure in humans, Hypertension, 27, 481, 10.1161/01.HYP.27.3.481
Cogswell, 2012, Sodium and potassium intakes among US adults: NHANES 2003-2008, Am J Clin Nutr, 96, 647, 10.3945/ajcn.112.034413
Weinberger, 2001, Salt sensitivity, pulse pressure, and death in normal and hypertensive humans, Hypertension, 37, 429, 10.1161/01.HYP.37.2.429
Morimoto, 1997, Sodium sensitivity and cardiovascular events in patients with essential hypertension, Lancet, 350, 1734, 10.1016/S0140-6736(97)05189-1
Gu, 2013, Reproducibility of blood pressure responses to dietary sodium and potassium interventions: the GenSalt study, Hypertension, 62, 499, 10.1161/HYPERTENSIONAHA.113.01034
Poulter, 1984, Blood pressure and associated factors in a rural Kenyan community, Hypertension, 6, 810, 10.1161/01.HYP.6.6.810
He, 1991, Relation of electrolytes to blood pressure in men. The Yi people study, Hypertension, 17, 378, 10.1161/01.HYP.17.3.378
Zhang, 2013, Association between usual sodium and potassium intake and blood pressure and hypertension among U.S. adults: NHANES 2005–2010, PLoS ONE, 8
Kieneker, 2014, Urinary potassium excretion and risk of developing hypertension: the prevention of renal and vascular end-stage disease study, Hypertension, 64, 769, 10.1161/HYPERTENSIONAHA.114.03750
D'Elia, 2011, Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies, J Am Coll Cardiol, 57, 1210, 10.1016/j.jacc.2010.09.070
D'Elia, 2014, Potassium-rich diet and risk of stroke: updated meta-analysis, Nutr Metab Cardiovasc Dis, 24, 585, 10.1016/j.numecd.2014.03.001
Vinceti, 2016, Meta-analysis of potassium intake and the risk of stroke, J Am Heart Assoc., 5
Rodrigues, 2014, High potassium intake blunts the effect of elevated sodium intake on blood pressure levels, J Am Soc Hypertens, 8, 232, 10.1016/j.jash.2014.01.001
Khaw, 1988, The association between blood pressure, age, and dietary sodium and potassium: a population study, Circulation, 77, 53, 10.1161/01.CIR.77.1.53
Cook, 2009, Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study, Arch Intern Med, 169, 32, 10.1001/archinternmed.2008.523
Lesniak, 2001, Exercise and hypertension, Curr Opin Cardiol, 16, 356, 10.1097/00001573-200111000-00007
Hayashi, 1999, Walking to work and the risk for hypertension in men: the Osaka Health Survey, Ann Intern Med, 131, 21, 10.7326/0003-4819-131-1-199907060-00005
Leary, 2000, The influence of physical activity on the variability of ambulatory blood pressure, Am J Hypertens, 13, 1067, 10.1016/S0895-7061(00)01186-9
Carnethon, 2003, Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors, JAMA, 290, 3092, 10.1001/jama.290.23.3092
Liu, 2014, Effects of cardiorespiratory fitness on blood pressure trajectory with aging in a cohort of healthy men, J Am Coll Cardiol, 64, 1245, 10.1016/j.jacc.2014.06.1184
Lian, 1915, L'alcoholisme cause d'hypertension arterielle, Bull Acad Med (Paris), 74, 525
Klatsky, 2010, Alcohol and cardiovascular mortality: common sense and scientific truth, J Am Coll Cardiol, 55, 1336, 10.1016/j.jacc.2009.10.057
Chen, 2008, Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis, Circulation, 117, 3171, 10.1161/CIRCULATIONAHA.107.730366
Juhola, 2012, Childhood physical, environmental, and genetic predictors of adult hypertension: the cardiovascular risk in young Finns study, Circulation, 126, 402, 10.1161/CIRCULATIONAHA.111.085977
Parkinson, 2013, Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis, Pediatrics, 131, e1240, 10.1542/peds.2012-2177
de Jong, 2012, Systematic review and meta-analysis of preterm birth and later systolic blood pressure, Hypertension, 59, 226, 10.1161/HYPERTENSIONAHA.111.181784
Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141
Selassie, 2011, Progression is accelerated from prehypertension to hypertension in blacks, Hypertension, 58, 579, 10.1161/HYPERTENSIONAHA.111.177410
Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group, Ann Intern Med, 130, 461, 10.7326/0003-4819-130-6-199903160-00002
Funder, 2008, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 93, 3266, 10.1210/jc.2008-0104
Funder, 2016, The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 101, 1889, 10.1210/jc.2015-4061
Pedrosa, 2011, Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension, Hypertension, 58, 811, 10.1161/HYPERTENSIONAHA.111.179788
Kump, 1994, Assessment of the validity and utility of a sleep-symptom questionnaire, Am J. Respir Crit Care Med, 150, 735, 10.1164/ajrccm.150.3.8087345
Johns, 1991, A new method for measuring daytime sleepiness: the Epworth sleepiness scale, Sleep, 14, 540, 10.1093/sleep/14.6.540
Grossman, 2012, Drug-induced hypertension: an unappreciated cause of secondary hypertension, Am J Med, 125, 14, 10.1016/j.amjmed.2011.05.024
Lenders, 2014, Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 1915, 10.1210/jc.2014-1498
Nieman, 2008, The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 93, 1526, 10.1210/jc.2008-0125
Lurbe, 2009, Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension, J Hypertens, 27, 1719, 10.1097/HJH.0b013e32832f4f6b
Berglund, 1976, Prevalence of primary and secondary hypertension: studies in a random population sample, Br Med J, 2, 554, 10.1136/bmj.2.6035.554
Hassan-Smith, 2011, Inherited forms of mineralocorticoid hypertension, Curr Opin Endocrinol Diabetes Obes, 18, 177, 10.1097/MED.0b013e3283469444
Katznelson, 2014, Acromegaly: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 3933, 10.1210/jc.2014-2700
1993, The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V), Arch Intern Med, 153, 154, 10.1001/archinte.1993.00410020010002
Grossman, 2012, Drug-induced hypertension: an unappreciated cause of secondary hypertension, Am J Med, 125, 14, 10.1016/j.amjmed.2011.05.024
Ong, 2011, How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids, Endocrinol Metab Clin North Am., 40, 393, 10.1016/j.ecl.2011.01.010
Rossi, 2011, Drug-related hypertension and resistance to antihypertensive treatment: a call for action, J Hypertens, 29, 2295, 10.1097/HJH.0b013e32834c465d
Tachjian, 2010, Use of herbal products and potential interactions in patients with cardiovascular diseases, J Am Coll Cardiol, 55, 515, 10.1016/j.jacc.2009.07.074
Grossman, 2008, Secondary hypertension: interfering substances, J Clin Hypertens (Greenwich), 10, 556, 10.1111/j.1751-7176.2008.07758.x
Goldstein, 2011, Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 42, 517, 10.1161/STR.0b013e3181fcb238
Cortese, 2013, Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents, J Child Psychol Psychiatry, 54, 227, 10.1111/jcpp.12036
Wolraich, 2011, ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents, Pediatrics, 128, 1007, 10.1542/peds.2011-2654
Newcomer, 2007, Metabolic considerations in the use of antipsychotic medications: a review of recent evidence, J Clin Psychiatry, 68, 20
Willey, 2014, Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study, J Am Heart Assoc., 3
Mesas, 2011, The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis, Am J Clin Nutr, 94, 1113, 10.3945/ajcn.111.016667
Liu, 2013, Immunosuppressant utilization and cardiovascular complications among Chinese patients after kidney transplantation: a systematic review and analysis, Int Urol Nephrol, 45, 885, 10.1007/s11255-012-0294-x
Penninga, 2013, Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients, Cochrane Database Syst Rev., 5
Xue, 2014, Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis, Chin Med J, 127, 2376, 10.3760/cma.j.issn.0366-6999.20140518
Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151
Montori, 2002, Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature, Endocrinol Metab Clin North Am., 31, 619, 10.1016/S0889-8529(02)00013-0
Funder, 2008, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 93, 3266, 10.1210/jc.2008-0104
Funder, 2016, The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 101, 1889, 10.1210/jc.2015-4061
Mulatero, 2004, Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents, J Clin Endocrinol Metab, 89, 1045, 10.1210/jc.2003-031337
Hannemann, 2012, Prevalence of primary aldosteronism in patient's cohorts and in population-based studies–a review of the current literature, Horm Metab Res., 44, 157, 10.1055/s-0031-1295438
Rossi, 2006, Renal damage in primary aldosteronism: results of the PAPY Study, Hypertension, 48, 232, 10.1161/01.HYP.0000230444.01215.6a
Milliez, 2005, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism, J Am Coll Cardiol, 45, 1243, 10.1016/j.jacc.2005.01.015
Mulatero, 2013, Long-term cardio- and cerebrovascular events in patients with primary aldosteronism, J Clin Endocrinol Metab, 98, 4826, 10.1210/jc.2013-2805
Rossi, 2013, Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism, Hypertension, 62, 62, 10.1161/HYPERTENSIONAHA.113.01316
Fourkiotis, 2013, Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism, Eur J Endocrinol, 168, 75, 10.1530/EJE-12-0631
Cooper, 2014, Stenting and medical therapy for atherosclerotic renal-artery stenosis, N Engl J Med, 370, 13, 10.1056/NEJMoa1310753
Riaz, 2014, Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis, Am J Cardiol, 114, 1116, 10.1016/j.amjcard.2014.06.033
Olin, 2012, The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients, Circulation, 125, 3182, 10.1161/CIRCULATIONAHA.112.091223
Lamawansa, 1995, Short-term and long-term outcome following renovascular reconstruction, Cardiovasc Surg, 3, 50, 10.1016/0967-2109(95)92903-U
Trinquart, 2010, Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis, Hypertension, 56, 525, 10.1161/HYPERTENSIONAHA.110.152918
Barbe, 2010, Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea, Am J Respir Crit Care Med, 181, 718, 10.1164/rccm.200901-0050OC
Martinez-Garcia, 2013, Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial, JAMA, 310, 2407, 10.1001/jama.2013.281250
Lozano, 2010, Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial, J Hypertens, 28, 2161, 10.1097/HJH.0b013e32833b9c63
Muxfeldt, 2015, Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial, Hypertension. Hypertension, 65, 736, 10.1161/HYPERTENSIONAHA.114.04852
Pedrosa, 2013, Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial, Chest, 144, 1487, 10.1378/chest.13-0085
Marin, 2005, Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study, Lancet, 365, 1046, 10.1016/S0140-6736(05)74229-X
Marshall, 2008, Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study, Sleep, 31, 1079
Nieto, 2000, Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study, JAMA, 283, 1829, 10.1001/jama.283.14.1829
Peppard, 2000, Prospective study of the association between sleep-disordered breathing and hypertension, N Engl J Med, 342, 1378, 10.1056/NEJM200005113421901
Marin, 2012, Association between treated and untreated obstructive sleep apnea and risk of hypertension, JAMA, 307, 2169, 10.1001/jama.2012.3418
Pedrosa, 2011, Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension, Hypertension, 58, 811, 10.1161/HYPERTENSIONAHA.111.179788
Muxfeldt, 2014, Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension, Am J Hypertens, 27, 1069, 10.1093/ajh/hpu023
McEvoy, 2016, CPAP for prevention of cardiovascular events in obstructive sleep apnea, N Engl J Med, 375, 919, 10.1056/NEJMoa1606599
Whelton, 2002, Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program, JAMA, 288, 1882, 10.1001/jama.288.15.1882
1993, National High Blood Pressure Education Program Working Group report on primary prevention of hypertension, Arch Intern Med, 153, 186, 10.1001/archinte.1993.00410020042003
Whelton, 2004, Hypertension curriculum review: epidemiology and the prevention of hypertension, J Clin Hypertens (Greenwich), 6, 636, 10.1111/j.1524-6175.2004.03609.x
Whelton, 1998, Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group, JAMA, 279, 839, 10.1001/jama.279.11.839
Whelton, 2015, The elusiveness of population-wide high blood pressure control, Annu Rev Public Health, 36, 109, 10.1146/annurev-publhealth-031914-122949
1993, National High Blood Pressure Education Program Working Group report on primary prevention of hypertension, Arch Intern Med, 153, 186, 10.1001/archinte.1993.00410020042003
Cook, 2007, Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Prevention (TOHP), BMJ, 334, 885, 10.1136/bmj.39147.604896.55
Rodgers, 1999, Blood pressure and the global burden of cardiovascular disease, Clin Exp Hypertens, 21, 543, 10.3109/10641969909060987
Qin, 2009, Modelling the potential impact of population-wide and targeted high-risk blood pressure-lowering strategies on cardiovascular disease in China, Eur J Cardiovasc Prev Rehabil, 16, 96, 10.1097/HJR.0b013e32831fd6de
Zulman, 2008, The relative merits of population-based and targeted prevention strategies, Milbank Q, 86, 557, 10.1111/j.1468-0009.2008.00534.x
Neter, 2003, Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials, Hypertension, 42, 878, 10.1161/01.HYP.0000094221.86888.AE
Whelton, 1997, Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group, Am J Clin Nutr, 65, 652S, 10.1093/ajcn/65.2.652S
1992, The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I, JAMA, 267, 1213, 10.1001/jama.1992.03480090061028
Sacks, 2001, Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group, N Engl J Med, 344, 3, 10.1056/NEJM200101043440101
Appel, 2003, Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial, JAMA, 289, 2083
Appel, 1997, A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group, N Engl J Med, 336, 1117, 10.1056/NEJM199704173361601
Mozaffarian, 2014, Global sodium consumption and death from cardiovascular causes, N Engl J Med, 371, 624, 10.1056/NEJMoa1304127
Aburto, 2013, Effect of lower sodium intake on health: systematic review and meta-analyses, BMJ, 346, f1326, 10.1136/bmj.f1326
He, 2013, Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials, BMJ, 346, f1325, 10.1136/bmj.f1325
Graudal, 2012, Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review), Am J Hypertens, 25, 1, 10.1038/ajh.2011.210
Whelton, 1998, Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group, JAMA, 279, 839, 10.1001/jama.279.11.839
Whelton, 1997, Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials, JAMA, 277, 1624, 10.1001/jama.1997.03540440058033
Geleijnse, 2003, Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials, J Hum Hypertens, 17, 471, 10.1038/sj.jhh.1001575
2012
Whelton, 2014, Health effects of sodium and potassium in humans, Curr Opin Lipidol, 25, 75, 10.1097/MOL.0000000000000033
Aburto, 2013, Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses, BMJ, 346, f1378, 10.1136/bmj.f1378
Cornelissen, 2013, Exercise training for blood pressure: a systematic review and meta-analysis, J Am Heart Assoc., 2
Carlson, 2014, Isometric exercise training for blood pressure management: a systematic review and meta-analysis, Mayo Clin Proc., 89, 327, 10.1016/j.mayocp.2013.10.030
Garcia-Hermoso, 2013, Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials, Obes Rev., 14, 919, 10.1111/obr.12054
Rossi, 2013, The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example, Can J Cardiol, 29, 622, 10.1016/j.cjca.2013.02.010
Whelton, 2002, Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials, Ann Intern Med, 136, 493, 10.7326/0003-4819-136-7-200204020-00006
Xin, 2001, Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials, Hypertension, 38, 1112, 10.1161/hy1101.093424
Roerecke, 2017, The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis, Lancet Public Health, 2, e108, 10.1016/S2468-2667(17)30003-8
Stewart, 2008, Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study, Addiction, 103, 1622, 10.1111/j.1360-0443.2008.02317.x
Dickinson, 2006, Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials, J Hypertens, 24, 215, 10.1097/01.hjh.0000199800.72563.26
Wallace, 1988, Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption, BMJ, 297, 663, 10.1136/bmj.297.6649.663
Lang, 1995, Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group, J Epidemiol Community Health, 49, 610, 10.1136/jech.49.6.610
National Institute on Alcohol Abuse and Alcoholism (NIAAA). What Is A Standard Drink? Available at: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink. Accessed August 16, 2017.
Blumenthal, 2010, Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study, Arch Intern Med, 170, 126, 10.1001/archinternmed.2009.470
Inder, 2016, Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit, Hypertens Res., 39, 88, 10.1038/hr.2015.111
Khalesi, 2014, Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials, Hypertension, 64, 897, 10.1161/HYPERTENSIONAHA.114.03469
Dong, 2013, Effect of probiotic fermented milk on blood pressure: a meta-analysis of randomised controlled trials, Br J Nutr, 110, 1188, 10.1017/S0007114513001712
Cicero, 2011, Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials, J Hum Hypertens, 25, 425, 10.1038/jhh.2010.85
Rebholz, 2012, Dietary protein intake and blood pressure: a meta-analysis of randomized controlled trials, Am J Epidemiol, 176, S27, 10.1093/aje/kws245
Tielemans, 2013, Intake of total protein, plant protein and animal protein in relation to blood pressure: a meta-analysis of observational and intervention studies, J Hum Hypertens, 27, 564, 10.1038/jhh.2013.16
Dong, 2013, Effects of high-protein diets on body weight, glycaemic control, blood lipids and blood pressure in type 2 diabetes: meta-analysis of randomised controlled trials, Br J Nutr, 110, 781, 10.1017/S0007114513002055
Whelton, 2005, Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials, J Hypertens, 23, 475, 10.1097/01.hjh.0000160199.51158.cf
Streppel, 2005, Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials, Arch Intern Med, 165, 150, 10.1001/archinte.165.2.150
Rodriguez-Leyva, 2013, Potent antihypertensive action of dietary flaxseed in hypertensive patients, Hypertension, 62, 1081, 10.1161/HYPERTENSIONAHA.113.02094
Campbell, 2013, A systematic review of fish-oil supplements for the prevention and treatment of hypertension, Eur J Prev Cardiol, 20, 107, 10.1177/2047487312437056
van Mierlo, 2006, Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials, J Hum Hypertens, 20, 571, 10.1038/sj.jhh.1002038
Cormick, 2015, Calcium supplementation for prevention of primary hypertension, Cochrane Database Syst Rev., 6
Kass, 2012, Effect of magnesium supplementation on blood pressure: a meta-analysis, Eur J Clin Nutr, 66, 411, 10.1038/ejcn.2012.4
Zhang, 2016, Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials, Hypertension, 68, 324, 10.1161/HYPERTENSIONAHA.116.07664
Bazzano, 2014, Effects of low-carbohydrate and low-fat diets: a randomized trial, Ann Intern Med, 161, 309, 10.7326/M14-0180
Nordmann, 2006, Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials, Arch Intern Med, 166, 285, 10.1001/archinte.166.3.285
Yokoyama, 2014, Vegetarian diets and blood pressure: a meta-analysis, JAMA Intern Med, 174, 577, 10.1001/jamainternmed.2013.14547
Nordmann, 2011, Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors, Am J Med, 124, 841, 10.1016/j.amjmed.2011.04.024
Rossi, 2011, Drug-related hypertension and resistance to antihypertensive treatment: a call for action, J Hypertens, 29, 2295, 10.1097/HJH.0b013e32834c465d
Nagele, 2014, Clinical effectiveness of stress-reduction techniques in patients with hypertension: systematic review and meta-analysis, J Hypertens, 32, 1936, 10.1097/HJH.0000000000000298
Rohner, 2015, A systematic review and metaanalysis on the effects of garlic preparations on blood pressure in individuals with hypertension, Am J Hypertens, 28, 414, 10.1093/ajh/hpu165
Egan, 2010, Does dark chocolate have a role in the prevention and management of hypertension? Commentary on the evidence, Hypertension, 55, 1289, 10.1161/HYPERTENSIONAHA.110.151522
Ried, 2010, Does chocolate reduce blood pressure? A meta-analysis, BMC Med, 8, 39, 10.1186/1741-7015-8-39
Liu, 2014, Effects of tea intake on blood pressure: a meta-analysis of randomised controlled trials, Br J Nutr, 112, 1043, 10.1017/S0007114514001731
Steffen, 2012, The effect of coffee consumption on blood pressure and the development of hypertension: a systematic review and meta-analysis, J Hypertens, 30, 2245, 10.1097/HJH.0b013e3283588d73
Wang, 2013, Yoga for essential hypertension: a systematic review, PLoS ONE, 8
Dickinson, 2008, Relaxation therapies for the management of primary hypertension in adults: a Cochrane review, J Hum Hypertens, 22, 809, 10.1038/jhh.2008.65
Lee, 2007, Qigong for hypertension: a systematic review of randomized clinical trials, J Hypertens, 25, 1525, 10.1097/HJH.0b013e328092ee18
Yeh, 2008, The effect of tai chi exercise on blood pressure: a systematic review, Prev Cardiol, 11, 82, 10.1111/j.1751-7141.2008.07565.x
Canter, 2004, Insufficient evidence to conclude whether or not transcendental meditation decreases blood pressure: results of a systematic review of randomized clinical trials, J Hypertens, 22, 2049, 10.1097/00004872-200411000-00002
Whelton, 2002, Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program, JAMA, 288, 1882, 10.1001/jama.288.15.1882
Estruch, 2013, Mediterranean diet for primary prevention of cardiovascular disease, N Engl J Med, 369, 676
Wing, 2013, Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes, N Engl J Med, 369, 145, 10.1056/NEJMoa1212914
Aucott, 2009, Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review, Hypertension, 54, 756, 10.1161/HYPERTENSIONAHA.109.135178
Straznicky, 2010, European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality?, J Hypertens, 28, 637, 10.1097/HJH.0b013e32833778e1
Jensen, 2014, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, J Am Coll Cardiol, 63, 2985, 10.1016/j.jacc.2013.11.004
Ryan, 2014, The pharmacological and surgical management of adults with obesity, J Fam Pract, 63, S21
Chang, 2014, The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012, JAMA Surg, 149, 275, 10.1001/jamasurg.2013.3654
Svetkey, 1999, Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial, Arch Intern Med, 159, 285, 10.1001/archinte.159.3.285
Filippini, 2017, The effect of potassium supplementation on blood pressure in hypertensive subjects: a systematic review and meta-analysis, Int J Cardiol, 230, 127, 10.1016/j.ijcard.2016.12.048
National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure With DASH–How Do I Make the DASH? Available at: https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to. Accessed September 18, 2017.
Top 10 DASH Diet Tips. Available at: http://dashdiet.org/dash_diet_tips.asp. Accessed September 18, 2017.
van Bommel, 2012, Potassium treatment for hypertension in patients with high salt intake: a meta-analysis, Int J Clin Pharmacol Ther, 50, 478, 10.5414/CP201724
He, 2011, Effect of dietary protein supplementation on blood pressure, Circulation, 124, 589, 10.1161/CIRCULATIONAHA.110.009159
Cook, 2014, Lower levels of sodium intake and reduced cardiovascular risk, Circulation, 129, 981, 10.1161/CIRCULATIONAHA.113.006032
Cook, 2007, Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Orevention (TOHP), BMJ, 334, 885, 10.1136/bmj.39147.604896.55
Pimenta, 2009, Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial, Hypertension, 54, 475, 10.1161/HYPERTENSIONAHA.109.131235
Huggins, 2011, Influence of dietary modifications on the blood pressure response to antihypertensive medication, Br J Nutr, 105, 248, 10.1017/S0007114510003223
He, 2013, Plasma sodium and blood pressure in individuals on haemodialysis, J Hum Hypertens, 27, 85, 10.1038/jhh.2012.9
Whelton, 2014, Sodium, potassium, blood pressure, and cardiovascular disease in humans, Curr Hypertens Rep, 16, 465
Weinberger, 1986, Definitions and characteristics of sodium sensitivity and blood pressure resistance, Hypertension, 8, II127, 10.1161/01.HYP.8.6_Pt_2.II127
Mattes, 1991, Relative contributions of dietary sodium sources, J Am Coll Nutr, 10, 383, 10.1080/07315724.1991.10718167
Anderson, 2010, Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study, J Am Diet Assoc., 110, 736, 10.1016/j.jada.2010.02.007
Whelton, 2012, Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations, Circulation, 126, 2880, 10.1161/CIR.0b013e318279acbf
Cobb, 2012, Strategies to reduce dietary sodium intake, Curr Treat Options Cardiovasc Med, 14, 425, 10.1007/s11936-012-0182-9
McGuire, 2010, 49
He, 1991, Effect of migration on blood pressure: the Yi People Study, Epidemiology, 2, 88, 10.1097/00001648-199103000-00002
Stamler, 1997, The INTERSALT Study: background, methods, findings, and implications, Am J Clin Nutr, 65, 626S, 10.1093/ajcn/65.2.626S
Zhang, 2013, Association between usual sodium and potassium intake and blood pressure and hypertension among U.S. adults: NHANES 2005-2010, PLoS ONE, 8
Mente, 2014, Association of urinary sodium and potassium excretion with blood pressure, N Engl J Med, 371, 601, 10.1056/NEJMoa1311989
Kieneker, 2014, Urinary potassium excretion and risk of developing hypertension: the prevention of renal and vascular end-stage disease study, Hypertension, 64, 769, 10.1161/HYPERTENSIONAHA.114.03750
Bazzano, 2001, Dietary potassium intake and risk of stroke in US men and women: National Health and Nutrition Examination Survey I epidemiologic follow-up study, Stroke, 32, 1473, 10.1161/01.STR.32.7.1473
Ascherio, 1998, Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men, Circulation, 98, 1198, 10.1161/01.CIR.98.12.1198
Seth, 2014, Potassium intake and risk of stroke in women with hypertension and nonhypertension in the Women's Health Initiative, Stroke, 45, 2874, 10.1161/STROKEAHA.114.006046
D'Elia, 2011, Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies, J Am Coll Cardiol, 57, 1210, 10.1016/j.jacc.2010.09.070
Bazzano, 2002, Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, Am J Clin Nutr, 76, 93, 10.1093/ajcn/76.1.93
Gu, 2013, Reproducibility of blood pressure responses to dietary sodium and potassium interventions: the GenSalt study, Hypertension, 62, 499, 10.1161/HYPERTENSIONAHA.113.01034
Cook, 2009, Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study, Arch Intern Med, 169, 32, 10.1001/archinternmed.2008.523
Whelton, 1995, The effect of potassium supplementation in persons with a high-normal blood pressure. Results from phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group, Ann Epidemiol, 5, 85, 10.1016/1047-2797(94)00053-V
2015
2005
Cornelissen, 2009, Influence of exercise at lower and higher intensity on blood pressure and cardiovascular risk factors at older age, J Hypertens, 27, 753, 10.1097/HJH.0b013e328322cf60
Klatsky, 2008, Alcohol and hypertension: a review, J Am Soc Hypertens, 2, 307, 10.1016/j.jash.2008.03.010
2005
Cushman, 1998, Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure, Arch Intern Med, 158, 1197, 10.1001/archinte.158.11.1197
Rimm, 1999, Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors, BMJ, 319, 1523, 10.1136/bmj.319.7224.1523
Mukamal, 2012, Understanding the mechanisms that link alcohol and lower risk of coronary heart disease, Clin Chem., 58, 664, 10.1373/clinchem.2011.181628
Klatsky, 2010, Alcohol and cardiovascular mortality: common sense and scientific truth, J Am Coll Cardiol, 55, 1336, 10.1016/j.jacc.2009.10.057
Mukamal, 2010, Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002, J Am Coll Cardiol, 55, 1328, 10.1016/j.jacc.2009.10.056
Chang, 2016, Antihypertensive medications and the prevalence of hyperkalemia in a large health system, Hypertension, 67, 1181, 10.1161/HYPERTENSIONAHA.116.07363
Persu, 2004, Recent insights in the development of organ damage caused by hypertension, Acta Cardiol, 59, 369, 10.2143/AC.59.4.2005202
Allen, 2014, Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age, JAMA, 311, 490, 10.1001/jama.2013.285122
Pletcher, 2008, Prehypertension during young adulthood and coronary calcium later in life, Ann Intern Med, 149, 91, 10.7326/0003-4819-149-2-200807150-00005
Juhola, 2013, Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium, Circulation, 128, 217, 10.1161/CIRCULATIONAHA.113.001614
Santos, 2014, Alterations in cardiac structure and function in hypertension, Curr Hypertens Rep, 16, 428, 10.1007/s11906-014-0428-x
Devereux, 1999, Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences, Hypertens Res., 22, 1, 10.1291/hypres.22.1
Gidding, 2013, Longitudinal determinants of left ventricular mass and geometry: the Coronary Artery Risk Development in Young Adults (CARDIA) Study, Circ Cardiovasc Imaging, 6, 769, 10.1161/CIRCIMAGING.112.000450
Fox, 2015, Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans, J Am Heart Assoc., 4
Lieb, 2009, Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring study, Circulation, 119, 3085, 10.1161/CIRCULATIONAHA.108.824243
Liebson, 1995, Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS), Circulation, 91, 698, 10.1161/01.CIR.91.3.698
Fagard, 2009, Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies, Hypertension, 54, 1084, 10.1161/HYPERTENSIONAHA.109.136655
Norman, 1995, Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: results of a correlated data base approach, J Am Coll Cardiol, 26, 1022, 10.1016/0735-1097(95)00269-5
da Costa, 2008, Correlation of electrocardiographic left ventricular hypertrophy criteria with left ventricular mass by echocardiogram in obese hypertensive patients, J Electrocardiol, 41, 724, 10.1016/j.jelectrocard.2008.05.010
Bacharova, 2014, The role of ECG in the diagnosis of left ventricular hypertrophy, Curr Cardiol Rev., 10, 257, 10.2174/1573403X10666140514103220
Bang, 2014, Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction–a LIFE review, J Electrocardiol, 47, 630, 10.1016/j.jelectrocard.2014.07.003
Pewsner, 2007, Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review, BMJ, 335, 711, 10.1136/bmj.39276.636354.AE
Rautaharju, 2014, Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: a critical appraisal, J Electrocardiol, 47, 649, 10.1016/j.jelectrocard.2014.06.002
Armstrong, 2012, LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice, J Am Coll Cardiol Img, 5, 837, 10.1016/j.jcmg.2012.06.003
Greenland, 2010, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 56, e50, 10.1016/j.jacc.2010.09.001
Devereux, 2004, Prognostic significance of left ventricular mass change during treatment of hypertension, JAMA, 292, 2350, 10.1001/jama.292.19.2350
Armstrong, 2014, Framingham score and LV mass predict events in young adults: CARDIA study, Int J Cardiol, 172, 350, 10.1016/j.ijcard.2014.01.003
Okwuosa, 2015, Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study, Am Heart J, 169, 155, 10.1016/j.ahj.2014.09.013
Zalawadiya, 2015, Left ventricular hypertrophy and risk reclassification for coronary events in multi-ethnic adults, Eur J Prev Cardiol, 22, 673, 10.1177/2047487314530383
Lloyd-Jones, 2005, Hypertension in adults across the age spectrum: current outcomes and control in the community, JAMA, 294, 466, 10.1001/jama.294.4.466
Ozyilmaz, 2013, Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events, Nephrol Dial Transplant, 28, 2805, 10.1093/ndt/gft254
Peters, 2013, Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals, Stroke, 44, 2394, 10.1161/STROKEAHA.113.001624
Schoenfeld, 2013, The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review, Semin Arthritis Rheum, 43, 77, 10.1016/j.semarthrit.2012.12.002
Lawes, 2002, Blood pressure and coronary heart disease: a review of the evidence, Semin Vasc Med, 2, 355, 10.1055/s-2002-36765
Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8
Takashima, 2012, Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years, J Hypertens, 30, 2299, 10.1097/HJH.0b013e328359a9f7
Murakami, 2014, Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions, J Epidemiol, 24, 96
van Dieren, 2012, Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes, Diabetes Res Clin Pract, 98, 83, 10.1016/j.diabres.2012.05.002
Sundstrom, 2014, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet, 384, 591, 10.1016/S0140-6736(14)61212-5
Turnbull, 2005, Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials, Arch Intern Med, 165, 1410, 10.1001/archinte.165.12.1410
Wang, 2005, Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome, Hypertension, 45, 907, 10.1161/01.HYP.0000165020.14745.79
Turnbull, 2008, Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials, Eur Heart J, 29, 2669, 10.1093/eurheartj/ehn427
Turnbull, 2008, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials, BMJ, 336, 1121, 10.1136/bmj.39548.738368.BE
Du, 2009, Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study, Eur Heart J, 30, 1128, 10.1093/eurheartj/ehp055
Czernichow, 2010, Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial, Hypertension, 55, 1193, 10.1161/HYPERTENSIONAHA.109.140624
Heerspink, 2010, Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease, Eur Heart J, 31, 2888, 10.1093/eurheartj/ehq139
Ninomiya, 2010, Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial, J Hypertens, 28, 1141, 10.1097/HJH.0b013e328338a89c
Collier, 2011, Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), J Hypertens, 29, 583, 10.1097/HJH.0b013e328342c845
Ninomiya, 2013, Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. Blood Pressure Lowering Treatment Trialists' Collaboration, BMJ, 347, f5680, 10.1136/bmj.f5680
Redon, 2012, Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial), J Am Coll Cardiol, 59, 74, 10.1016/j.jacc.2011.09.040
Ogden, 2000, Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification, Hypertension, 35, 539, 10.1161/01.HYP.35.2.539
van der Leeuw, 2015, Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation, Hypertension, 65, 115, 10.1161/HYPERTENSIONAHA.114.04421
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8
Sundstrom, 2014, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet, 384, 591, 10.1016/S0140-6736(14)61212-5
Thomopoulos, 2014, Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials, J Hypertens, 32, 2296, 10.1097/HJH.0000000000000379
Sundstrom, 2015, Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis, Ann Intern Med, 162, 184, 10.7326/M14-0773
Thompson, 2011, Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis, JAMA, 305, 913, 10.1001/jama.2011.250
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Czernichow, 2011, The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials, J Hypertens, 29, 4, 10.1097/HJH.0b013e32834000be
Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8
van Dieren, 2012, Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes, Diabetes Res Clin Pract, 98, 83, 10.1016/j.diabres.2012.05.002
Montgomery, 2003, The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis, J Hypertens, 21, 1753, 10.1097/00004872-200309000-00026
Kassai, 2005, Treatment of high blood pressure and gain in event-free life expectancy, Vasc Health Risk Manag, 1, 163, 10.2147/vhrm.1.2.163.64086
ACC/AHA Pooled Cohort Equations. Available at: (http://tools.acc.org/ASCVD-Risk-Estimator/. Accessed November 3, 2017.
Rubinstein, 2010, Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina, BMC Public Health, 10, 627, 10.1186/1471-2458-10-627
Baker, 2000, Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated, BMJ, 320, 680, 10.1136/bmj.320.7236.680
Gaziano, 2005, Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level, Circulation, 112, 3569, 10.1161/CIRCULATIONAHA.105.535922
Eddy, 2011, Individualized guidelines: the potential for increasing quality and reducing costs, Ann Intern Med, 154, 627, 10.7326/0003-4819-154-9-201105030-00008
Marchant, 2011, The global risk approach should be better applied in French hypertensive patients: a comparison between simulation and observation studies, PLoS ONE, 6, 10.1371/journal.pone.0017508
Cadilhac, 2012, Organized blood pressure control programs to prevent stroke in Australia: would they be cost-effective?, Stroke, 43, 1370, 10.1161/STROKEAHA.111.634949
Cobiac, 2012, Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study, BMC Public Health, 12, 398, 10.1186/1471-2458-12-398
Cobiac, 2012, Which interventions offer best value for money in primary prevention of cardiovascular disease?, PLoS ONE, 7, 10.1371/journal.pone.0041842
Karmali, 2017, Global risk assessment to guide blood pressure management in cardiovascular disease prevention, Hypertension, 69, e2, 10.1161/HYPERTENSIONAHA.116.08249
Muntner, 2017, Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment, J Am Coll Cardiol, 69, 2446, 10.1016/j.jacc.2017.02.066
Sussman, 2013, Using benefit-based tailored treatment to improve the use of antihypertensive medications, Circulation, 128, 2309, 10.1161/CIRCULATIONAHA.113.002290
van der Leeuw, 2014, Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects, Eur Heart J, 35, 837, 10.1093/eurheartj/ehu004
Mendis, 2007, World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries, J Hypertens, 25, 1578, 10.1097/HJH.0b013e3282861fd3
van Dis, 2012, Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach, Neth Heart J, 20, 320, 10.1007/s12471-012-0268-8
Nelson, 2013, Primary prevention of cardiovascular disease: new guidelines, technologies and therapies, Med J Aust, 198, 606, 10.5694/mja12.11054
2014, Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3), Heart, 100, ii1, 10.1136/heartjnl-2014-305693
2007
Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2304, 10.1016/j.jacc.2014.03.016
Sheridan, 2008, Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature, BMC Health Serv Res., 8, 60, 10.1186/1472-6963-8-60
Sheridan, 2010, The effect of giving global coronary risk information to adults: a systematic review, Arch Intern Med, 170, 230, 10.1001/archinternmed.2009.516
Viera, 2010, Global risk of coronary heart disease: assessment and application, Am Fam Physician, 82, 265
Sheridan, 2011, A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies, BMC Health Serv Res., 11, 331, 10.1186/1472-6963-11-331
Brett, 2012, The Fremantle Primary Prevention Study: a multicentre randomised trial of absolute cardiovascular risk reduction, Br J Gen Pract, 62, e22, 10.3399/bjgp12X616337
Sekaran, 2013, Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes, BMC Cardiovasc Disord, 13, 90, 10.1186/1471-2261-13-90
Sheridan, 2014, The effect of a decision aid intervention on decision making about coronary heart disease risk reduction: secondary analyses of a randomized trial, BMC Med Inform Decis Mak, 14, 14, 10.1186/1472-6947-14-14
Jansen, 2014, General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study, BMJ Open, 4, 10.1136/bmjopen-2014-004812
Vagholkar, 2014, Influence of cardiovascular absolute risk assessment on prescribing of antihypertensive and lipid-lowering medications: a cluster randomized controlled trial, Am Heart J, 167, 28, 10.1016/j.ahj.2013.10.002
Rafter, 2005, Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk, N Z Med J, 118, U1676
Yong, 2007, Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease, Med J Aust, 186, 622, 10.5694/j.1326-5377.2007.tb01078.x
Webster, 2009, Gaps in cardiovascular disease risk management in Australian general practice, Med J Aust, 191, 324, 10.5694/j.1326-5377.2009.tb02816.x
Frikke-Schmidt, 2010, Common clinical practice versus new PRIM score in predicting coronary heart disease risk, Atherosclerosis, 213, 532, 10.1016/j.atherosclerosis.2010.07.028
Heeley, 2010, Cardiovascular risk perception and evidence–practice gaps in Australian general practice (the AusHEART study), Med J Aust, 192, 254, 10.5694/j.1326-5377.2010.tb03502.x
Shillinglaw, 2012, Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians, BMC Health Serv Res., 12, 20, 10.1186/1472-6963-12-20
Game, 2001, Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus, Diabetes Obes Metab, 3, 279, 10.1046/j.1463-1326.2001.00131.x
Bastuji-Garin, 2002, The Framingham prediction rule is not valid in a European population of treated hypertensive patients, J Hypertens, 20, 1973, 10.1097/00004872-200210000-00016
Menotti, 2002, The estimate of cardiovascular risk. Theory, tools and problems, Ann Ital Med Int, 17, 81
de Visser, 2003, Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population, J Intern Med, 253, 553, 10.1046/j.1365-2796.2003.01137.x
Persson, 2003, Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample, J Hypertens, 21, 1089, 10.1097/00004872-200306000-00008
Doust, 2012, Prioritising CVD prevention therapy–absolute risk versus individual risk factors, Aust Fam Physician, 41, 805
Allan, 2013, Agreement among cardiovascular disease risk calculators, Circulation, 127, 1948, 10.1161/CIRCULATIONAHA.112.000412
2002, Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function?, Heart, 88, 222, 10.1136/heart.88.3.222
van den Hoogen, 2000, The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group, N Engl J Med, 342, 1, 10.1056/NEJM200001063420101
Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2935, 10.1016/j.jacc.2013.11.005
Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002
Thomopoulos, 2014, Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk–overview and meta-analyses of randomized trials, J Hypertens, 32, 2305, 10.1097/HJH.0000000000000380
Julius, 2006, Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med, 354, 1685, 10.1056/NEJMoa060838
Julius, 2008, TROPHY study: outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension, J Am Soc Hypertens, 2, 39, 10.1016/j.jash.2007.07.005
Luders, 2008, The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League, J Hypertens, 26, 1487, 10.1097/HJH.0b013e3282ff8864
Fuchs, 2016, Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the PREVER Prevention Randomized Clinical Trial, J Am Heart Assoc, 5
Lonn, 2016, Blood-pressure lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med, 374, 2009, 10.1056/NEJMoa1600175
Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404
Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005
Carson, 2011, Ethnic differences in hypertension incidence among middle-aged and older adults: the Multi-Ethnic study of Atherosclerosis, Hypertension, 57, 1101, 10.1161/HYPERTENSIONAHA.110.168005
Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317
Parving, 2012, Cardiorenal end points in a trial of aliskiren for type 2 diabetes, N Engl J Med, 367, 2204, 10.1056/NEJMoa1208799
Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154
1967, Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg, JAMA, 202, 1028, 10.1001/jama.1967.03130240070013
1979, Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group, JAMA, 242, 2562, 10.1001/jama.1979.03300230018021
1991, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group, JAMA, 265, 3255, 10.1001/jama.1991.03460240051027
Kostis, 2011, Association between chlorthalidone treatment of systolic hypertension and long-term survival, JAMA, 306, 2588, 10.1001/jama.2011.1821
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Thomopoulos, 2014, Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials, J Hypertens, 32, 2296, 10.1097/HJH.0000000000000379
Czernichow, 2011, The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials, J Hypertens, 29, 4, 10.1097/HJH.0b013e32834000be
Fretheim, 2012, Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis, BMC Med, 10, 33, 10.1186/1741-7015-10-33
Cushman, 2002, Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), J Clin Hypertens (Greenwich), 4, 393, 10.1111/j.1524-6175.2002.02045.x
Gradman, 2011, Combination therapy in hypertension, J Clin Hypertens (Greenwich), 13, 146, 10.1111/j.1751-7176.2010.00397.x
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
Thomopoulos, 2016, Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels–updated overview and meta-analyses of randomized trials, J Hypertens, 34, 613, 10.1097/HJH.0000000000000881
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Verdecchia, 2016, More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis, Hypertension, 68, 642, 10.1161/HYPERTENSIONAHA.116.07608
Bangalore, 2017, Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials, Am J Med, 30, 707, 10.1016/j.amjmed.2017.01.004
Bundy, 2017, Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis, JAMA Cardiol, 2, 775, 10.1001/jamacardio.2017.1421
Julius, 2006, Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med, 354, 1685, 10.1056/NEJMoa060838
Lawes, 2002, Blood pressure and coronary heart disease: a review of the evidence, Semin Vasc Med, 2, 355, 10.1055/s-2002-36765
Lonn, 2016, Blood-pressure lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med, 374, 2009, 10.1056/NEJMoa1600175
Neaton, 1993, Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group, JAMA, 270, 713, 10.1001/jama.1993.03510060059034
Reboussin, 2018, Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults, J Am Coll Cardiol, 71, 2176, 10.1016/j.jacc.2017.11.004
Brunstrom, 2016, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses, BMJ, 352, i717, 10.1136/bmj.i717
Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8
Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
2013, Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial, Lancet, 382, 507, 10.1016/S0140-6736(13)60852-1
Perkovic, 2015, Redefining blood-pressure targets–SPRINT starts the marathon, N Engl J Med, 373, 2175, 10.1056/NEJMe1513301
Lawes, 2003, Blood pressure and cardiovascular disease in the Asia Pacific region, J Hypertens, 21, 707, 10.1097/00004872-200304000-00013
Allen, 2014, Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age, JAMA, 311, 490, 10.1001/jama.2013.285122
Ference, 2014, Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension, Hypertension, 63, 1182, 10.1161/HYPERTENSIONAHA.113.02734
Psaty, 2003, Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis, JAMA, 289, 2534, 10.1001/jama.289.19.2534
2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981
Ferrucci, 1997, Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled, JAMA, 277, 728, 10.1001/jama.1997.03540330050034
Curtis, 2008, Incidence and prevalence of heart failure in elderly persons, 1994-2003, Arch Intern Med, 168, 418, 10.1001/archinternmed.2007.80
Bleumink, 2004, Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study, Eur Heart J, 25, 1614, 10.1016/j.ehj.2004.06.038
Bertoni, 2004, Heart failure prevalence, incidence, and mortality in the elderly with diabetes, Diabetes Care, 27, 699, 10.2337/diacare.27.3.699
Ogedegbe, 2015, Comparative effectiveness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites, J Am Coll Cardiol, 66, 1224, 10.1016/j.jacc.2015.07.021
Leenen, 2006, Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, Hypertension, 48, 374, 10.1161/01.HYP.0000231662.77359.de
2003, Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Hypertension, 42, 239, 10.1161/01.HYP.0000086521.95630.5A
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Thomopoulos, 2015, Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs-overview and meta-analyses, J Hypertens, 33, 1321, 10.1097/HJH.0000000000000447
Zhang, 2017, Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis, J Am Soc. Hypertens, 11, 394, 10.1016/j.jash.2017.05.001
Larochelle, 2014, β-Blockers in hypertension: studies and meta-analyses over the years, Can J Cardiol, 30, S16, 10.1016/j.cjca.2014.02.012
Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
Law, 2003, Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials, BMJ, 326, 1427, 10.1136/bmj.326.7404.1427
Bangalore, 2007, Fixed-dose combinations improve medication compliance: a meta-analysis, Am J Med, 120, 713, 10.1016/j.amjmed.2006.08.033
Jamerson, 2008, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients, N Engl J Med, 359, 2417, 10.1056/NEJMoa0806182
Sundstrom, 2015, Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis, Ann Intern Med, 162, 184, 10.7326/M14-0773
Luders, 2008, The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League, J Hypertens, 26, 1487, 10.1097/HJH.0b013e3282ff8864
1977, Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study, JAMA, 237, 255, 10.1001/jama.1977.03270300059008
Neaton, 1993, Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group, JAMA, 270, 713, 10.1001/jama.1993.03510060059034
Senn, 2004, Individual response to treatment: is it a valid assumption?, BMJ, 329, 966, 10.1136/bmj.329.7472.966
Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404
Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005
Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404
Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005
Xu, 2015, Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study, BMJ, 350, h158, 10.1136/bmj.h158
Brennan, 2010, Disease management to promote blood pressure control among African Americans, Popul Health Manag, 13, 65, 10.1089/pop.2009.0019
Bosworth, 2009, Two self-management interventions to improve hypertension control: a randomized trial, Ann Intern Med, 151, 687, 10.7326/0000605-200911170-00148
Bosworth, 2011, Home blood pressure management and improved blood pressure control: results from a randomized controlled trial, Arch Intern Med, 171, 1173, 10.1001/archinternmed.2011.276
Green, 2008, Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial, JAMA, 299, 2857, 10.1001/jama.299.24.2857
Heisler, 2012, Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial, Circulation, 125, 2863, 10.1161/CIRCULATIONAHA.111.089169
Margolis, 2013, Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial, JAMA, 310, 46, 10.1001/jama.2013.6549
Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019
Gerhard-Herman, 2017, 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 69, e71, 10.1016/j.jacc.2016.11.007
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Bundy, 2017, Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis, JAMA Cardiol, 2, 775, 10.1001/jamacardio.2017.1421
Leenen, 2006, Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, Hypertension, 48, 374, 10.1161/01.HYP.0000231662.77359.de
Zanchetti, 2006, Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial, J Hypertens, 24, 2163, 10.1097/01.hjh.0000249692.96488.46
2003, Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Hypertension, 42, 239, 10.1161/01.HYP.0000086521.95630.5A
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001
Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301
Leon, 1981, Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris, Am J Cardiol, 48, 131, 10.1016/0002-9149(81)90582-8
Staessen, 1997, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Lancet, 350, 757, 10.1016/S0140-6736(97)05381-6
Freemantle, 1999, Beta Blockade after myocardial infarction: systematic review and meta regression analysis, BMJ, 318, 1730, 10.1136/bmj.318.7200.1730
de Peuter, 2009, A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure, Neth J Med, 67, 284
Bavry, 2010, Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy, Hypertension, 55, 48, 10.1161/HYPERTENSIONAHA.109.142240
Piller, 2014, Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT, J Gen Intern Med, 29, 1475, 10.1007/s11606-014-2947-1
Rosendorff, 2015, Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension, J Am Coll Cardiol, 65, 1998, 10.1016/j.jacc.2015.02.038
Ekelund, 1976, Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests, Br Heart J, 38, 155, 10.1136/hrt.38.2.155
Aronow, 1980, The effect of timolol vs placebo on angina pectoris, Circulation, 61, 66, 10.1161/01.CIR.61.1.66
Aronow, 2013, Angina pectoris in the elderly, 215
Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, J Am Coll Cardiol, 58, 2432, 10.1016/j.jacc.2011.10.824
Carlberg, 2004, Atenolol in hypertension: is it a wise choice?, Lancet, 364, 1684, 10.1016/S0140-6736(04)17355-8
Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151
Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468
Thomopoulos, 2016, Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels–updated overview and meta-analyses of randomized trials, J Hypertens, 34, 613, 10.1097/HJH.0000000000000881
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Visser, 1998, High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study, Am J Clin Nutr, 68, 584, 10.1093/ajcn/68.3.584
Goodpaster, 2006, The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study, J Gerontol A Biol Sci Med Sci., 61, 1059, 10.1093/gerona/61.10.1059
Butler, 2011, Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study, Heart, 97, 1304, 10.1136/hrt.2011.225482
Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8
Goldstein, 1991, Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group, Circulation, 83, 52, 10.1161/01.CIR.83.1.52
Aronow, 1998, Normal left ventricular ejection fraction in older persons with congestive heart failure, Chest, 113, 867, 10.1378/chest.113.4.867
Aronow, 1999, Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites, Am J Cardiol, 84, 611, 10.1016/S0002-9149(99)00392-6
Gottdiener, 2002, Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study, Ann Intern Med, 137, 631, 10.7326/0003-4819-137-8-200210150-00006
Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256
Vasan, 1999, Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort, J Am Coll Cardiol, 33, 1948, 10.1016/S0735-1097(99)00118-7
Amery, 1985, Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial, Lancet, 1, 1349, 10.1016/S0140-6736(85)91783-0
Kostis, 1997, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group, JAMA, 278, 212, 10.1001/jama.1997.03550030052033
Beckett, 2008, Treatment of hypertension in patients 80 years of age or older, N Engl J Med, 358, 1887, 10.1056/NEJMoa0801369
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Davis, 2008, Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, Circulation, 118, 2259, 10.1161/CIRCULATIONAHA.107.762229
Piller, 2011, Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Circulation, 124, 1811, 10.1161/CIRCULATIONAHA.110.012575
Pfeffer, 2015, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, Circulation, 131, 34, 10.1161/CIRCULATIONAHA.114.013255
Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019
van Veldhuisen, 2009, Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure), J Am Coll Cardiol, 53, 2150, 10.1016/j.jacc.2009.02.046
Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7
Massie, 2008, Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 2456, 10.1056/NEJMoa0805450
Aronow, 1998, Normal left ventricular ejection fraction in older persons with congestive heart failure, Chest, 113, 867, 10.1378/chest.113.4.867
Aronow, 1999, Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites, Am J Cardiol, 84, 611, 10.1016/S0002-9149(99)00392-6
Vasan, 1999, Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort, J Am Coll Cardiol, 33, 1948, 10.1016/S0735-1097(99)00118-7
Gottdiener, 2002, Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study, Ann Intern Med, 137, 631, 10.7326/0003-4819-137-8-200210150-00006
Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256
Lee, 2009, Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute, Circulation, 119, 3070, 10.1161/CIRCULATIONAHA.108.815944
Bhuiyan, 2011, Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma, Curr Cardiovasc Risk Rep, 5, 440, 10.1007/s12170-011-0184-2
Kato, 2008, Exaggerated hypertensive response to exercise in patients with diastolic heart failure, Hypertens Res., 31, 679, 10.1291/hypres.31.679
St Gyalai-Korpos, 2008, Hypertensive acute pulmonary oedema as expression of diastolic heart failure, Rom J Intern Med, 46, 153
Kostis, 1997, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group, JAMA, 278, 212, 10.1001/jama.1997.03550030052033
Beckett, 2008, Treatment of hypertension in patients 80 years of age or older, N Engl J Med, 358, 1887, 10.1056/NEJMoa0801369
Piller, 2011, Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), Circulation, 124, 1811, 10.1161/CIRCULATIONAHA.110.012575
Davis, 2008, Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, Circulation, 118, 2259, 10.1161/CIRCULATIONAHA.107.762229
Redfield, 2013, Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial, JAMA, 309, 1268, 10.1001/jama.2013.2024
Klahr, 1994, The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group, N Engl J Med, 330, 877, 10.1056/NEJM199403313301301
Ruggenenti, 2005, Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial, Lancet, 365, 939, 10.1016/S0140-6736(05)71082-5
Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421
Upadhyay, 2011, Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier, Ann Intern Med, 154, 541, 10.7326/0003-4819-154-8-201104190-00335
Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468
Jafar, 2003, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis, Ann Intern Med, 139, 244, 10.7326/0003-4819-139-4-200308190-00006
Lambers Heerspink, 2008, Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality, Am J Epidemiol, 168, 897, 10.1093/aje/kwn209
Lambers Heerspink, 2010, Comparison of different measures of urinary protein excretion for prediction of renal events, J Am Soc Nephrol, 21, 1355, 10.1681/ASN.2010010063
Contreras, 2005, Blood pressure control, drug therapy, and kidney disease, Hypertension, 46, 44, 10.1161/01.HYP.0000166746.04472.60
Esnault, 2008, The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study, Clin Ther, 30, 482, 10.1016/j.clinthera.2008.03.006
Marin, 2001, A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease, J Hypertens, 19, 1871, 10.1097/00004872-200110000-00023
Giatras, 1997, Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, Ann Intern Med, 127, 337, 10.7326/0003-4819-127-5-199709010-00001
Reboussin, 2018, Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults, J Am Coll Cardiol, 71, 2176, 10.1016/j.jacc.2017.11.004
Muntner, 2010, Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study, Am J Kidney Dis, 55, 441, 10.1053/j.ajkd.2009.09.014
James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427
2014
Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151
2012, KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease, Kidney Int Suppl (2011), 2, 337
Kanno, 2010, Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure monitoring for determining prevalent risk of chronic kidney disease: the Ohasama study, Hypertens Res., 33, 1192, 10.1038/hr.2010.139
Terawaki, 2008, Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population: the Ohasama study, Hypertens Res., 31, 2129, 10.1291/hypres.31.2129
Minutolo, 2014, Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study, Am J Kidney Dis, 64, 744, 10.1053/j.ajkd.2014.06.014
Drawz, 2016, Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage, Clin J Am Soc Nephrol, 11, 642, 10.2215/CJN.08530815
Agarwal, 2006, Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease, Kidney Int, 69, 1175, 10.1038/sj.ki.5000247
Navaneethan, 2015, Cause-specific deaths in non-dialysis-dependent CKD, J Am Soc Nephrol, 26, 2512, 10.1681/ASN.2014101034
Matsushita, 2010, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Chronic Kidney Disease Prognosis Consortium, Lancet, 375, 2073, 10.1016/S0140-6736(10)60674-5
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2935, 10.1016/j.jacc.2013.11.005
Kovesdy, 2016, Age and outcomes associated with BP in patients with incident CKD, Clin J Am Soc Nephrol, 11, 821, 10.2215/CJN.08660815
Weiss, 2015, Systolic BP and mortality in older adults with CKD, Clin J Am Soc Nephrol, 10, 1553, 10.2215/CJN.11391114
Williamson, 2016, Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial, JAMA, 315, 2673, 10.1001/jama.2016.7050
Holtkamp, 2011, An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function, Kidney Int, 80, 282, 10.1038/ki.2011.79
Hricik, 1983, Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney, N Engl J Med, 308, 373, 10.1056/NEJM198302173080706
Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292
Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317
Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154
Parving, 2012, Cardiorenal end points in a trial of aliskiren for type 2 diabetes, N Engl J Med, 367, 2204, 10.1056/NEJMoa1208799
Peterson, 1995, Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study, Ann Intern Med, 123, 754, 10.7326/0003-4819-123-10-199511150-00003
Appel, 2010, Intensive blood-pressure control in hypertensive chronic kidney disease, N Engl J Med, 363, 918, 10.1056/NEJMoa0910975
Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8
Thomopoulos, 2016, Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels–updated overview and meta-analyses of randomized trials, J Hypertens, 34, 613, 10.1097/HJH.0000000000000881
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Ninomiya, 2013, Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials, BMJ, 347, f5680, 10.1136/bmj.f5680
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Cross, 2009, Antihypertensive treatment for kidney transplant recipients, Cochrane Database Syst Rev., 10.1002/14651858.CD003598.pub2
Cosio, 2001, Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients, Kidney Int, 59, 1158, 10.1046/j.1523-1755.2001.0590031158.x
Peschke, 1999, Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients, Clin Nephrol, 51, 290
Mange, 2000, Arterial hypertension and renal allograft survival, JAMA, 283, 633, 10.1001/jama.283.5.633
Mange, 2004, Blood pressure and the survival of renal allografts from living donors, J Am Soc Nephrol, 15, 187, 10.1097/01.ASN.0000104574.04006.08
Taler, 1999, Cyclosporin-induced hypertension: incidence, pathogenesis and management, Drug Saf, 20, 437, 10.2165/00002018-199920050-00004
Taler, 1996, Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine, Transplantation, 62, 1588, 10.1097/00007890-199612150-00011
Woodle, 2008, A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy, Ann Surg, 248, 564, 10.1097/SLA.0b013e318187d1da
Vincenti, 2008, A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients, Am J Transplant, 8, 307, 10.1111/j.1600-6143.2007.02057.x
Rostaing, 2013, Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study, Am J Transplant, 13, 2875, 10.1111/ajt.12460
Opelz, 2005, Improved long-term outcomes after renal transplantation associated with blood pressure control, Am J Transplant, 5, 2725, 10.1111/j.1600-6143.2005.01093.x
Hillebrand, 2009, Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients, Transpl Int, 22, 1073, 10.1111/j.1432-2277.2009.00922.x
Wadei, 2007, Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index, J Am Soc Nephrol, 18, 1607, 10.1681/ASN.2006111289
Ambrosi, 2014, Home blood pressure monitoring in heart transplant recipients: comparison with ambulatory blood pressure monitoring, Transplantation, 97, 363, 10.1097/01.TP.0000435704.55805.f9
Haydar, 2004, Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients, Transplantation, 77, 849, 10.1097/01.TP.0000115345.16853.51
Jennings, 2008, Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation, Ann Pharmacother, 42, 116, 10.1345/aph.1K471
Benjamin, 2017, Heart disease and stroke statistics–2017 update: a report from the American Heart Association, Circulation, 135, e146, 10.1161/CIR.0000000000000485
Boan, 2014, Lowering of blood pressure for recurrent stroke prevention, Stroke, 45, 2506, 10.1161/STROKEAHA.114.003666
Anderson, 2013, Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage, N Engl J Med, 368, 2355, 10.1056/NEJMoa1214609
Qureshi, 2016, Intensive blood-pressure lowering in patients with acute cerebral hemorrhage, N Engl J Med, 375, 1033, 10.1056/NEJMoa1603460
Benjamin, 2017, Heart disease and stroke statistics–2017 update: a report from the American Heart Association, Circulation, 135, e146, 10.1161/CIR.0000000000000485
Zhang, 2008, Blood pressure and clinical outcome among patients with acute stroke in Inner Mongolia, China J Hypertens, 26, 1446, 10.1097/HJH.0b013e328300a24a
Rodriguez-Luna, 2013, Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage, Eur J Neurol, 20, 1277, 10.1111/ene.12180
Sakamoto, 2013, Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study, Stroke, 44, 1846, 10.1161/STROKEAHA.113.001212
Tsivgoulis, 2014, Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis, Neurology, 83, 1523, 10.1212/WNL.0000000000000917
2010, Antihypertensive treatment of acute cerebral hemorrhage, Crit Care Med, 38, 637, 10.1097/CCM.0b013e3181b9e1a5
Anderson, 2008, Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial, Lancet Neurol, 7, 391, 10.1016/S1474-4422(08)70069-3
1995, Tissue plasminogen activator for acute ischemic stroke, N Engl J Med, 333, 1581, 10.1056/NEJM199512143332401
Hacke, 2008, Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke, N Engl J Med, 359, 1317, 10.1056/NEJMoa0804656
Ahmed, 2009, Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR), Stroke, 40, 2442, 10.1161/STROKEAHA.109.548602
Robinson, 2010, Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial, Lancet Neurol, 9, 767, 10.1016/S1474-4422(10)70163-0
He, 2014, Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial, JAMA, 311, 479, 10.1001/jama.2013.282543
Wang, 2014, Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis, PLoS ONE, 9
Zhao, 2015, Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature, Medicine (Baltimore), 94, e896, 10.1097/MD.0000000000000896
Bath, 2014, Interventions for deliberately altering blood pressure in acute stroke, Cochrane Database Syst Rev., 10
Sandset, 2011, The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial, Lancet, 377, 741, 10.1016/S0140-6736(11)60104-9
Qureshi, 2007, Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States, Am J Emerg Med, 25, 32, 10.1016/j.ajem.2006.07.008
Leonardi-Bee, 2002, Blood pressure and clinical outcomes in the International Stroke Trial, Stroke, 33, 1315, 10.1161/01.STR.0000014509.11540.66
Castillo, 2004, Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome, Stroke, 35, 520, 10.1161/01.STR.0000109769.22917.B0
Vemmos, 2004, U-shaped relationship between mortality and admission blood pressure in patients with acute stroke, J Intern Med, 255, 257, 10.1046/j.1365-2796.2003.01291.x
Jauch, 2013, Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 44, 870, 10.1161/STR.0b013e318284056a
Liu, 2009, Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature, Hypertens Res., 32, 1032, 10.1038/hr.2009.139
Lakhan, 2009, Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis, Int Arch Med, 2, 30, 10.1186/1755-7682-2-30
2001, Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack, Lancet, 358, 1033, 10.1016/S0140-6736(01)06178-5
1995, Post-stroke antihypertensive treatment study. A preliminary result, Chin Med J, 108, 710
Lee, 2012, Renin-angiotensin system modulators modestly reduce vascular risk in persons with prior stroke, Stroke, 43, 113, 10.1161/STROKEAHA.111.632596
Wang, 2016, Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials, Medicine (Baltimore), 95, e3302, 10.1097/MD.0000000000003302
Katsanos, 2017, Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials, Hypertension, 69, 171, 10.1161/HYPERTENSIONAHA.116.08485
Benavente, 2013, Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. SPS3 Study Group, Lancet, 382, 507, 10.1016/S0140-6736(13)60852-1
Arima, 2006, Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial, J Hypertens, 24, 1201, 10.1097/01.hjh.0000226212.34055.86
Benjamin, 2017, Heart disease and stroke statistics–2017 update: a report from the American Heart Association, Circulation, 135, e146, 10.1161/CIR.0000000000000485
Dhamoon, 2006, Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study, Neurology, 66, 641, 10.1212/01.wnl.0000201253.93811.f6
Hardie, 2004, Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study, Stroke, 35, 731, 10.1161/01.STR.0000116183.50167.D9
Lovett, 2004, Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies, Neurology, 62, 569, 10.1212/01.WNL.0000110311.09970.83
Toschke, 2011, Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database, J Hypertens, 29, 154, 10.1097/HJH.0b013e32833f3897
Kernan, 2014, Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 45, 2160, 10.1161/STR.0000000000000024
Buse, 2007, Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association, Diabetes Care, 30, 162, 10.2337/dc07-9917
Ostergren, 2004, Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease, Eur Heart J, 25, 17, 10.1016/j.ehj.2003.10.033
Thompson, 2011, Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis, JAMA, 305, 913, 10.1001/jama.2011.250
Bavry, 2010, Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy, Hypertension, 55, 48, 10.1161/HYPERTENSIONAHA.109.142240
Zanchetti, 2006, Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial, J Hypertens, 24, 2163, 10.1097/01.hjh.0000249692.96488.46
Piller, 2014, Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT, J Gen Intern. Med, 29, 1475, 10.1007/s11606-014-2947-1
Emdin, 2015, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis, JAMA, 313, 603, 10.1001/jama.2014.18574
Arguedas, 2013, Blood pressure targets for hypertension in people with diabetes mellitus, Cochrane Database Syst Rev., 10
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3
Margolis, 2014, Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial, Diabetes Care, 37, 1721, 10.2337/dc13-2334
Soliman, 2015, Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial, Hypertension, 66, 1123, 10.1161/HYPERTENSIONAHA.115.06236
Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468
Bress, 2017, Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial, Diabetes Care, 40, 1401, 10.2337/dc17-0885
Turnbull, 2005, Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials, Arch Intern Med, 165, 1410, 10.1001/archinte.165.12.1410
Whelton, 2005, Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Arch Intern Med, 165, 1401, 10.1001/archinte.165.12.1401
Palmer, 2015, Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis, Lancet, 385, 2047, 10.1016/S0140-6736(14)62459-4
Schmieder, 2007, Renin-angiotensin system and cardiovascular risk, Lancet, 369, 1208, 10.1016/S0140-6736(07)60242-6
Reboussin, 2018, Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults, J Am Coll Cardiol, 71, 2176, 10.1016/j.jacc.2017.11.004
Kannel, 1991, The epidemiology of impaired glucose tolerance and hypertension, Am Heart J, 121, 1268, 10.1016/0002-8703(91)90432-H
Tarnow, 1994, Prevalence of arterial hypertension in diabetic patients before and after the JNC-V, Diabetes Care, 17, 1247, 10.2337/diacare.17.11.1247
Adler, 2000, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study, BMJ, 321, 412, 10.1136/bmj.321.7258.412
Stamler, 1993, Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434
Do, 2015, Blood pressure control for diabetic retinopathy, Cochrane Database Syst Rev., 1
Estacio, 2000, Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes, Diabetes Care, 23, B54
Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension, N Engl J Med, 338, 645, 10.1056/NEJM199803053381003
1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group, BMJ, 317, 703, 10.1136/bmj.317.7160.703
Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6
Reboldi, 2011, Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients, J Hypertens, 29, 1253, 10.1097/HJH.0b013e3283469976
Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8
Brunstrom, 2016, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses, BMJ, 352, i717, 10.1136/bmj.i717
Perkovic, 2015, Redefining blood-pressure targets–SPRINT starts the marathon, N Engl J Med, 373, 2175, 10.1056/NEJMe1513301
Mancia, 2011, Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET), Circulation, 124, 1727, 10.1161/CIRCULATIONAHA.110.008870
Wright, 2009, ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses, Arch Intern Med, 169, 832, 10.1001/archinternmed.2009.60
Lim, 2014, Pharmacological treatment and therapeutic perspectives of metabolic syndrome, Rev Endocr Metab Disord, 15, 329, 10.1007/s11154-014-9298-4
Owen, 2015, Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications, Curr Hypertens Rep, 17, 558, 10.1007/s11906-015-0558-9
Ruderman, 2015, Metabolic syndrome, 752
Mozumdar, 2011, Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006, Diabetes Care, 34, 216, 10.2337/dc10-0879
Chen, 2004, The metabolic syndrome and chronic kidney disease in U.S. adults, Ann Intern Med, 140, 167, 10.7326/0003-4819-140-3-200402030-00007
Chen, 2007, Association between the metabolic syndrome and chronic kidney disease in Chinese adults, Nephrol Dial Transplant, 22, 1100, 10.1093/ndt/gfl759
Barzilay, 2014, The glycemic effects of antihypertensive medications, Curr Hypertens Rep, 16, 410, 10.1007/s11906-013-0410-z
Kostis, 2005, Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes, Am J Cardiol, 95, 29, 10.1016/j.amjcard.2004.08.059
Wright, 2008, Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Arch Intern Med, 168, 207, 10.1001/archinternmed.2007.66
Wright, 2009, ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses, Arch Intern Med, 169, 832, 10.1001/archinternmed.2009.60
Laurent, 2014, Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome, Hypertension, 64, 709, 10.1161/HYPERTENSIONAHA.114.03282
Reisin, 2015, Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection, J Am Soc Hypertens, 9, 156, 10.1016/j.jash.2014.12.015
Healey, 2005, Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis, J Am Coll Cardiol, 45, 1832, 10.1016/j.jacc.2004.11.070
Zhao, 2015, Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials, J Biomed Res., 29, 475
Kistler, 2004, Electrophysiologic and electroanatomic changes in the human atrium associated with age, J Am Coll Cardiol, 44, 109, 10.1016/j.jacc.2004.03.044
January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, 64, e1, 10.1016/j.jacc.2014.03.022
Olesen, 2012, The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study, Thromb Haemost, 107, 1172, 10.1160/TH12-03-0175
Healey, 2003, Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target, Am J Cardiol, 91, 9G, 10.1016/S0002-9149(03)00227-3
Hansson, 1999, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, 1751, 10.1016/S0140-6736(99)10327-1
Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9
Wachtell, 2005, Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study, J Am Coll Cardiol, 45, 712, 10.1016/j.jacc.2004.10.068
Haywood, 2009, Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), J Am Coll Cardiol, 54, 2023, 10.1016/j.jacc.2009.08.020
Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0
Rieck, 2012, Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events, Hypertension, 60, 90, 10.1161/HYPERTENSIONAHA.112.194878
Eleid, 2013, Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction, Circulation, 128, 1349, 10.1161/CIRCULATIONAHA.113.003071
Bull, 2015, A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial), Eur Heart J Cardiovasc Imaging, 16, 834, 10.1093/ehjci/jev043
Chockalingam, 2004, Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS), Am Heart J, 147, E19, 10.1016/j.ahj.2003.10.017
Scognamiglio, 1994, Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function, N Engl J Med, 331, 689, 10.1056/NEJM199409153311101
Evangelista, 2005, Long-term vasodilator therapy in patients with severe aortic regurgitation, N Engl J Med, 353, 1342, 10.1056/NEJMoa050666
Genoni, 2001, Chronic beta-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection, Eur J Cardiothorac Surg, 19, 606, 10.1016/S1010-7940(01)00662-5
Suzuki, 2012, Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]), Am J Cardiol, 109, 122, 10.1016/j.amjcard.2011.08.012
Masuda, 1991, Prognosis of patients with medically treated aortic dissections, Circulation, 84, III7
Rampoldi, 2007, Simple risk models to predict surgical mortality in acute type A aortic dissection: the International Registry of Acute Aortic Dissection score, Ann Thorac Surg, 83, 55, 10.1016/j.athoracsur.2006.08.007
Suzuki, 2003, Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD), Circulation, 108, II312
Mehta, 2002, Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era, J Am Coll Cardiol, 40, 685, 10.1016/S0735-1097(02)02005-3
Chan, 2014, First-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissection, Cochrane Database Syst Rev., 2
Gaddum, 2015, Altered dependence of aortic pulse wave velocity on transmural pressure in hypertension revealing structural change in the aortic wall, Hypertension, 65, 362, 10.1161/HYPERTENSIONAHA.114.04370
Zhang, 2015, Prognostic impact of blood pressure variability on aortic dissection patients after endovascular therapy, Medicine (Baltimore), 94, e1591, 10.1097/MD.0000000000001591
Yoon, 2015, Hypertension prevalence and control among adults: United States, 2011-2014, NCHS Data Brief, 1
Margolis, 2007, Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, Hypertension, 50, 854, 10.1161/HYPERTENSIONAHA.107.092650
Cooper-DeHoff, 2006, Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients–findings from the International Verapamil SR/Trandolapril Study (INVEST), Am Heart J, 151, 1072, 10.1016/j.ahj.2005.05.024
Benjamin, 2017, Heart disease and stroke statistics–2017 update: a report from the American Heart Association, Circulation, 135, e146, 10.1161/CIR.0000000000000485
Centers for Disease Control and Prevention. Compressed Mortality File: Underlying Cause-of-Death 1999-2013. 2014. Available at: https://wonder.cdc.gov/mortsql.html. Accessed November 2, 2017.
Guzman, 2012, Epidemiology and management of hypertension in the Hispanic population: a review of the available literature. Am J Cardiovasc Drugs, Am J Cardiovasc Drugs, 12, 165, 10.2165/11631520-000000000-00000
Sorlie, 2014, Prevalence of hypertension, awareness, treatment, and control in the Hispanic Community Health Study/Study of Latinos, Am J Hypertens, 27, 793, 10.1093/ajh/hpu003
Rodriguez, 2014, Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association, Circulation, 130, 593, 10.1161/CIR.0000000000000071
Parsa, 2013, APOL1 risk variants, race, and progression of chronic kidney disease, N Engl J Med, 369, 2183, 10.1056/NEJMoa1310345
Lipkowitz, 2013, Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans, Kidney Int, 83, 114, 10.1038/ki.2012.263
Langefeld, 2015, Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial, Kidney Int, 87, 169, 10.1038/ki.2014.254
Grams, 2016, Race, APOL1 risk, and eGFR decline in the general population, J Am Soc Nephrol, 27, 2842, 10.1681/ASN.2015070763
Leenen, 2006, Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, Hypertension, 48, 374, 10.1161/01.HYP.0000231662.77359.de
Wright, 2009, ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses, Arch Intern Med, 169, 832, 10.1001/archinternmed.2009.60
Wright, 2005, Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril, JAMA, 293, 1595, 10.1001/jama.293.13.1595
Wright, 2008, Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Arch Intern Med, 168, 207, 10.1001/archinternmed.2007.66
2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421
Odedosu, 2012, Overcoming barriers to hypertension control in African Americans, Cleve Clin J Med, 79, 46, 10.3949/ccjm.79a.11068
Ferdinand, 2010, Management of high blood pressure in African Americans and the 2010 ISHIB consensus statement: meeting an unmet need, J Clin Hypertens (Greenwich), 12, 237, 10.1111/j.1751-7176.2010.00272.x
Flack, 2010, Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement, Hypertension, 56, 780, 10.1161/HYPERTENSIONAHA.110.152892
Jamerson, 1996, The impact of ethnicity on response to antihypertensive therapy, Am J Med, 101, 22S, 10.1016/S0002-9343(96)00265-3
Saunders, 1990, A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks, Arch Intern Med, 150, 1707, 10.1001/archinte.1990.00040031707020
Cushman, 2000, Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, Arch Intern Med, 160, 825, 10.1001/archinte.160.6.825
Brewster, 2004, Systematic review: antihypertensive drug therapy in black patients, Ann Intern Med, 141, 614, 10.7326/0003-4819-141-8-200410190-00009
Zanchetti, 2006, Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial, J Hypertens, 24, 2163, 10.1097/01.hjh.0000249692.96488.46
Jamerson, 2008, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients, N Engl J Med, 359, 2417, 10.1056/NEJMoa0806182
Woo, 1995, High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese, Br J Clin Pharmacol, 40, 141
Czernichow, 2011, The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials, J Hypertens, 29, 4, 10.1097/HJH.0b013e32834000be
Fretheim, 2012, Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis, BMC Med, 10, 33, 10.1186/1741-7015-10-33
Jafar, 2003, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis, Ann Intern Med, 139, 244, 10.7326/0003-4819-139-4-200308190-00006
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Benjamin, 2017, Heart disease and stroke statistics–2017 update: a report from the American Heart Association, Circulation, 135, e146, 10.1161/CIR.0000000000000485
Gueyffier, 1997, Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators, Ann Intern Med, 126, 761, 10.7326/0003-4819-126-10-199705150-00002
Turnbull, 2008, Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials, Eur Heart J, 29, 2669, 10.1093/eurheartj/ehn427
Turnbull, 2008, Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials, Eur Heart J, 29, 2669, 10.1093/eurheartj/ehn427
Wenger, 2016, Women, hypertension, and the Systolic Blood Pressure Intervention Trial, Am J Med, 129, 1030, 10.1016/j.amjmed.2016.06.022
Fletcher, 1988, Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP), J Hum Hypertens, 2, 219
Jansen, 2014, General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study, BMJ OPEN, 4, 10.1136/bmjopen-2014-004812
Lewis, 1996, Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study, Arch Intern Med, 156, 377, 10.1001/archinte.1996.00440040047006
Kloner, 1996, Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group, Am J Cardiol, 77, 713, 10.1016/S0002-9149(97)89205-3
Igho Pemu, 2008, Hypertension in women: part I, J Clin Hypertens (Greenwich), 10, 406, 10.1111/j.1751-7176.2008.06552.x
James, 2004, Management of hypertension before, during, and after pregnancy, Heart, 90, 1499, 10.1136/hrt.2004.035444
2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
2011
Pucci, 2015, Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits, Expert Rev Clin Pharmacol, 8, 221, 10.1586/17512433.2015.1005074
Moretti, 2012, The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, Obstet Gynecol Int, 2012, 658310, 10.1155/2012/658310
Ferrer, 2000, Management of mild chronic hypertension during pregnancy: a review, Obstet Gynecol, 96, 849
Garovic, 2013, Preeclampsia and the future risk of hypertension: the pregnant evidence, Curr Hypertens Rep, 15, 114, 10.1007/s11906-013-0329-4
Kessous, 2015, Long-term maternal atherosclerotic morbidity in women with pre-eclampsia, Heart, 101, 442, 10.1136/heartjnl-2014-306571
Veerbeek, 2015, Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension, Hypertension, 65, 600, 10.1161/HYPERTENSIONAHA.114.04850
Abalos, 2014, Antihypertensive drug therapy for mild to moderate hypertension during pregnancy, Cochrane Database Syst Rev., 2
Nabhan, 2011, Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension, Cochrane Database Syst Rev., 10.1002/14651858.CD006907.pub2
Magee, 2003, Oral beta-blockers for mild to moderate hypertension during pregnancy, Cochrane Database Syst Rev, 10.1002/14651858.CD002863
Magee, 2015, Less-tight versus tight control of hypertension in pregnancy, N Engl J Med, 372, 407, 10.1056/NEJMoa1404595
Duley, 2013, Drugs for treatment of very high blood pressure during pregnancy, Cochrane Database Syst Rev., 7
Gulati, 2017, Early identification of pregnant women at risk for preeclampsia: USPSTF recommendations on screening for preeclampsia, JAMA Cardiol, 2, 593, 10.1001/jamacardio.2017.1276
Henderson, 2017, Preeclampsia screening: evidence report and systematic review for the US Preventive Services Task Force, JAMA, 317, 1668, 10.1001/jama.2016.18315
Regitz-Zagrosek, 2011, ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC), Eur Heart J, 32, 3147, 10.1093/eurheartj/ehr218
2015, Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period, Obstet Gynecol, 125, 521, 10.1097/01.AOG.0000460762.59152.d7
Shimada, 2015, Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review, Hypertens Res., 38, 308, 10.1038/hr.2015.12
Williamson, 2016, Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial, JAMA, 315, 2673, 10.1001/jama.2016.7050
Ettinger, 1994, Self-reported causes of physical disability in older people: the Cardiovascular Health Study. CHS Collaborative Research Group, J Am Geriatr Soc., 42, 1035, 10.1111/j.1532-5415.1994.tb06206.x
Ferrucci, 1997, Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled, JAMA, 277, 728, 10.1001/jama.1997.03540330050034
den Ouden, 2014, Do subclinical vascular abnormalities precede impaired physical ability and ADL disability?, Exp Gerontol, 58, 1, 10.1016/j.exger.2014.06.002
Ezzati, 2002, Selected major risk factors and global and regional burden of disease, Lancet, 360, 1347, 10.1016/S0140-6736(02)11403-6
Duprez, 2008, Systolic hypertension in the elderly: addressing an unmet need, Am J Med, 121, 179, 10.1016/j.amjmed.2007.10.027
Egan, 2014, Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals, Circulation, 130, 1692, 10.1161/CIRCULATIONAHA.114.010676
Liu, 2015, Prevalence and trends of isolated systolic hypertension among untreated adults in the United States, J Am Soc Hypertens, 9, 197, 10.1016/j.jash.2015.01.002
1991, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group, JAMA, 265, 3255, 10.1001/jama.1991.03460240051027
Staessen, 1997, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Lancet, 350, 757, 10.1016/S0140-6736(97)05381-6
Liu, 1998, Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group, J Hypertens, 16, 1823, 10.1097/00004872-199816120-00016
Beckett, 2008, Treatment of hypertension in patients 80 years of age or older, N Engl J Med, 358, 1887, 10.1056/NEJMoa0801369
Tinetti, 2014, Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults, JAMA Intern Med, 174, 588, 10.1001/jamainternmed.2013.14764
Gangavati, 2011, Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study, J Am Geriatr Soc., 59, 383, 10.1111/j.1532-5415.2011.03317.x
Margolis, 2014, Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial, J Gen Intern Med, 29, 1599, 10.1007/s11606-014-2961-3
Bavishi, 2017, Outcomes of intensive blood pressure lowering in older hypertensive patients, J Am Coll Cardiol, 69, 486, 10.1016/j.jacc.2016.10.077
Gibbons, 2017, The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension, J Neurol, 264, 1567
Moser, 2013, The treatment of hypertension: a remarkable success story, J Clin Hypertens (Greenwich), 15, 88, 10.1111/jch.12033
2012, S1
2011, Pediatrics, 128, S213
Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
Flynn, 2014, Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association, Hypertension, 63, 1116, 10.1161/HYP.0000000000000007
O'Brien, 2013, European Society of Hypertension position paper on ambulatory blood pressure monitoring, J Hypertens, 31, 1731, 10.1097/HJH.0b013e328363e964
Flynn, 2017, Clinical practice guideline for screening and management of high blood pressure in children and adolescents, Pediatrics, 140, 10.1542/peds.2017-1904
Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141
Persell, 2011, Prevalence of resistant hypertension in the United States, 2003-2008, Hypertension, 57, 1076, 10.1161/HYPERTENSIONAHA.111.170308
Achelrod, 2015, Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations, Am J Hypertens, 28, 355, 10.1093/ajh/hpu151
Smith, 2014, Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study, J Am Heart Assoc., 3
Tanner, 2014, Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study, Am J Kidney Dis, 63, 781, 10.1053/j.ajkd.2013.11.016
Bangalore, 2014, Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease, Am J Med, 127, 71, 10.1016/j.amjmed.2013.07.038
Calhoun, 2014, Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort, Hypertension, 63, 451, 10.1161/HYPERTENSIONAHA.113.02026
Rosa, 2016, Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 Study, Hypertension, 67, 397, 10.1161/HYPERTENSIONAHA.115.06526
Bhatt, 2014, A controlled trial of renal denervation for resistant hypertension, N Engl J Med, 370, 1393, 10.1056/NEJMoa1402670
Bisognano, 2011, Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial, J Am Coll Cardiol, 58, 765, 10.1016/j.jacc.2011.06.008
Stergiou, 2005, Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy, J Hypertens, 23, 883, 10.1097/01.hjh.0000163159.22116.ab
Liu, 2015, Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis, J Hum Hypertens, 29, 159, 10.1038/jhh.2014.64
Williams, 2015, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial, Lancet, 386, 2059, 10.1016/S0140-6736(15)00257-3
Rodilla, 2009, Spironolactone and doxazosin treatment in patients with resistant hypertension, Rev Esp Cardiol, 62, 158, 10.1016/S0300-8932(09)70158-7
Dahal, 2015, The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies, Am J Hypertens, 28, 1376, 10.1093/ajh/hpv031
Agodoa, 2001, Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial, JAMA, 285, 2719, 10.1001/jama.285.21.2719
Farias, 2014, Impact of initial blood pressure on antihypertensive response in patients with acute hypertension, Am J Emerg Med, 32, 833, 10.1016/j.ajem.2014.03.021
Peacock, 2014, Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure–A Pilot Study (PRONTO), Am Heart J, 167, 529, 10.1016/j.ahj.2013.12.023
Papadopoulos, 2015, Cardiovascular hypertensive emergencies, Curr Hypertens Rep, 17, 5, 10.1007/s11906-014-0515-z
Manning, 2014, Control of blood pressure in hypertensive neurological emergencies, Curr. Hypertens Rep, 16, 436, 10.1007/s11906-014-0436-x
Rhoney, 2009, Intravenous therapy for hypertensive emergencies, part 1, Am J Health Syst Pharm, 66, 1343, 10.2146/ajhp080348.p1
Rhoney, 2009, Intravenous therapy for hypertensive emergencies, part 2, Am J Health Syst Pharm, 66, 1448, 10.2146/ajhp080348.p2
Keith, 1974, Some different types of essential hypertension: their course and prognosis, Am J Med Sci., 268, 336, 10.1097/00000441-197412000-00004
Perez, 2008, Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review, J Hum Hypertens, 22, 596, 10.1038/jhh.2008.25
Gifford, 1959, Current practices in general medicine. 7. Treatment of hypertensive emergencies including use of sodium nitroprusside, Proc Staff Meet Mayo Clin, 34, 387
Peacock, 2011, CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department, Crit Care, 15, R157, 10.1186/cc10289
Cannon, 2013, Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial, BMJ OPEN, 3, 10.1136/bmjopen-2012-002338
Varon, 2014, The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine?, Postgrad Med, 126, 124, 10.3810/pgm.2014.07.2790
Anderson, 2013, Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage, N Engl J Med, 368, 2355, 10.1056/NEJMoa1214609
Applegate, 1994, Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program, Arch Intern Med, 154, 2154, 10.1001/archinte.1994.00420190047006
Forette, 1998, Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, Lancet, 352, 1347, 10.1016/S0140-6736(98)03086-4
Forette, 2002, The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study, Arch Intern Med, 162, 2046, 10.1001/archinte.162.18.2046
Lithell, 2003, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial, J Hypertens, 21, 875, 10.1097/00004872-200305000-00011
Tzourio, 2003, Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease, Arch Intern Med, 163, 1069, 10.1001/archinte.163.9.1069
Peters, 2008, Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial, Lancet Neurol, 7, 683, 10.1016/S1474-4422(08)70143-1
Prince, 2015, 10
Brookmeyer, 2002, Survival following a diagnosis of Alzheimer disease, Arch Neurol, 59, 1764, 10.1001/archneur.59.11.1764
Qiu, 2005, The age-dependent relation of blood pressure to cognitive function and dementia, Lancet Neurol, 4, 487, 10.1016/S1474-4422(05)70141-1
Kivipelto, 2001, Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study, Neurology, 56, 1683, 10.1212/WNL.56.12.1683
Kuller, 2005, Determinants of vascular dementia in the Cardiovascular Health Cognition Study, Neurology, 64, 1548, 10.1212/01.WNL.0000160115.55756.DE
Liao, 1996, Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study, Stroke, 27, 2262, 10.1161/01.STR.27.12.2262
Longstreth, 1996, Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study, Stroke, 27, 1274, 10.1161/01.STR.27.8.1274
O'Rourke, 2005, Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy, Hypertension, 46, 200, 10.1161/01.HYP.0000168052.00426.65
Skoog, 1998, A review on blood pressure and ischaemic white matter lesions, Dement Geriatr Cogn Disord, 9, 13, 10.1159/000051184
Hughes, 2016, Hypertension and its role in cognitive function: current evidence and challenges for the future, Am J Hypertens, 29, 149, 10.1093/ajh/hpv180
Staessen, 1997, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Lancet, 350, 757, 10.1016/S0140-6736(97)05381-6
Czernichow, 2010, Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial, Hypertension, 55, 1193, 10.1161/HYPERTENSIONAHA.109.140624
Bosch, 2002, Use of ramipril in preventing stroke: double blind randomised trial, BMJ, 324, 699, 10.1136/bmj.324.7339.699
Williamson, 2014, Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial, JAMA Intern Med, 174, 324, 10.1001/jamainternmed.2013.13656
Anderson, 2011, Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies, Lancet Neurol, 10, 43, 10.1016/S1474-4422(10)70250-7
Nunes, 2012, New insights into hypertension-associated erectile dysfunction, Curr Opin Nephrol Hypertens, 21, 163, 10.1097/MNH.0b013e32835021bd
Johannes, 2000, Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study, J Urol, 163, 460
Ayta, 1999, The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences, BJU Int, 84, 50, 10.1046/j.1464-410x.1999.00142.x
Thompson, 2005, Erectile dysfunction and subsequent cardiovascular disease, JAMA, 294, 2996, 10.1001/jama.294.23.2996
Shin, 2011, Erectile dysfunction: a disease marker for cardiovascular disease, Cardiol Rev., 19, 5, 10.1097/CRD.0b013e3181fb7eb8
Martin, 2014, Predictors of sexual dysfunction incidence and remission in men, J Sex Med, 11, 1136
Vasquez, 2016, Novel therapeutic targets for phosphodiesterase 5 inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis, Curr Pharm Biotechnol, 17, 347, 10.2174/1389201017666151223123904
Ghiadoni, 2008, Phosphodiesterase 5 inhibition in essential hypertension, Curr Hypertens Rep, 10, 52, 10.1007/s11906-008-0011-4
Al Khaja, 2016, Antihypertensive drugs and male sexual dysfunction: a review of adult hypertension guideline recommendations, J Cardiovasc Pharmacol Ther, 21, 233, 10.1177/1074248415598321
Lindenauer, 2005, Perioperative beta-blocker therapy and mortality after major noncardiac surgery, N Engl J Med, 353, 349, 10.1056/NEJMoa041895
Shammash, 2001, Perioperative beta-blocker withdrawal and mortality in vascular surgical patients, Am Heart J, 141, 148, 10.1067/mhj.2001.111547
Wallace, 2010, Association of the pattern of use of perioperative β-blockade and postoperative mortality, Anesthesiology, 113, 794, 10.1097/ALN.0b013e3181f1c061
Andersson, 2014, Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study, JAMA Intern Med, 174, 336, 10.1001/jamainternmed.2013.11349
Hoeks, 2007, Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients, Eur J Vasc Endovasc Surg, 33, 13, 10.1016/j.ejvs.2006.06.019
Barrett, 2007, Association of ambulatory use of statins and beta-blockers with long-term mortality after vascular surgery, J Hosp Med, 2, 241, 10.1002/jhm.160
London, 2013, Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery, JAMA, 309, 1704, 10.1001/jama.2013.4135
Turan, 2012, Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery, Anesth Analg, 114, 552, 10.1213/ANE.0b013e318241f6af
Rosenman, 2008, Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period, J Hosp Med, 3, 319, 10.1002/jhm.323
Roshanov, 2017, Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort, Anesthesiology, 126, 16, 10.1097/ALN.0000000000001404
Fleisher, 2002, Preoperative evaluation of the patient with hypertension, JAMA, 287, 2043, 10.1001/jama.287.16.2043
Howell, 2004, Hypertension, hypertensive heart disease and perioperative cardiac risk, Br J Anaesth, 92, 570, 10.1093/bja/aeh091
Hart, 1981, Withdrawal syndromes and the cessation of antihypertensive therapy, Arch Intern Med, 141, 1125, 10.1001/archinte.1981.00340090021007
Devereaux, 2008, Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. POISE Study Group, Lancet, 371, 1839, 10.1016/S0140-6736(08)60601-7
Charlson, 1989, The preoperative and intraoperative hemodynamic predictors of postoperative myocardial infarction or ischemia in patients undergoing noncardiac surgery, Ann Surg, 210, 637, 10.1097/00000658-198911000-00012
Cheung, 2006, Exploring an optimum intra/postoperative management strategy for acute hypertension in the cardiac surgery patient, J Card Surg, 21, S8, 10.1111/j.1540-8191.2006.00214.x
Dix, 2001, Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery, Br J Anaesth, 86, 789, 10.1093/bja/86.6.789
Haas, 2004, Acute postoperative hypertension: a review of therapeutic options, Am J Health Syst Pharm, 61, 1661, 10.1093/ajhp/61.16.1661
Aronson, 2008, The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients, Anesth Analg, 107, 1110, 10.1213/ane.0b013e31818240db
Espinosa, 2016, Perioperative use of clevidipine: a systematic review and meta-analysis, PLoS ONE, 11, 10.1371/journal.pone.0150625
Fleisher, 2014, 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 130, 2215, 10.1161/CIR.0000000000000105
Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, J Am Coll Cardiol, 58, 2432, 10.1016/j.jacc.2011.10.824
1997, The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, Arch Intern Med, 157, 2413, 10.1001/archinte.1997.00440420033005
Wolfsthal, 1993, Is blood pressure control necessary before surgery?, Med Clin North Am., 77, 349, 10.1016/S0025-7125(16)30256-5
Goldman, 1979, Risks of general anesthesia and elective operation in the hypertensive patient, Anesthesiology, 50, 285, 10.1097/00000542-197904000-00002
Towne, 1980, The relationship of postoperative hypertension to complications following carotid endarterectomy, Surgery, 88, 575
Aronson, 2002, Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery, Anesth Analg, 94, 1079, 10.1097/00000539-200205000-00005
Foex, 1971, Studies of anaesthesia in relation to hypertension. 3. Pulmonary gas exchange during spontaneous ventilation, Br J Anaesth, 43, 644, 10.1093/bja/43.7.644
Gerber, 1979, Abrupt withdrawal of cardiovascular drugs, N Engl J Med, 301, 1234, 10.1056/NEJM197911293012210
Rangno, 1982, Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol, Am Heart J, 104, 473, 10.1016/0002-8703(82)90142-9
Walker, 1985, Abrupt withdrawal of atenolol in patients with severe angina. Comparison with the effects of treatment, Br Heart J, 53, 276, 10.1136/hrt.53.3.276
Claxton, 2001, A systematic review of the associations between dose regimens and medication compliance, Clin Ther, 23, 1296, 10.1016/S0149-2918(01)80109-0
Iskedjian, 2002, Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis, Clin Ther, 24, 302, 10.1016/S0149-2918(02)85026-3
Schroeder, 2004, How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials, Arch Intern Med, 164, 722, 10.1001/archinte.164.7.722
Bangalore, 2007, Fixed-dose combinations improve medication compliance: a meta-analysis, Am J Med, 120, 713, 10.1016/j.amjmed.2006.08.033
Gupta, 2010, Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis, Hypertension, 55, 399, 10.1161/HYPERTENSIONAHA.109.139816
Sherrill, 2011, Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence, J Clin Hypertens (Greenwich), 13, 898, 10.1111/j.1751-7176.2011.00550.x
Yang, 2010, Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives, Curr Med Res Opin, 26, 2065, 10.1185/03007995.2010.494462
Franklin, 2012, Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population, Hypertension, 59, 564, 10.1161/HYPERTENSIONAHA.111.180653
Holland, 2008, Identifying barriers to hypertension care: implications for quality improvement initiatives, Dis Manag, 11, 71, 10.1089/dis.2008.1120007
Berra, 2016, Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension, Hypertension, 68, 297, 10.1161/HYPERTENSIONAHA.116.07464
Gwadry-Sridhar, 2013, Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group, Value Health, 16, 863, 10.1016/j.jval.2013.03.1631
Petrilla, 2005, Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications, Int J Clin Pract, 59, 1441, 10.1111/j.1368-5031.2005.00704.x
Krousel-Wood, 2009, Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults, Med Clin North Am., 93, 753, 10.1016/j.mcna.2009.02.007
Nieuwlaat, 2014, Interventions for enhancing medication adherence, Cochrane Database Syst Rev., 11
Viswanathan, 2012, Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness), Evid RepTechnol Assess (Full Rep), 1
Kim, 2000, Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale, Prog Cardiovasc Nurs, 15, 90, 10.1111/j.1751-7117.2000.tb00211.x
Artinian, 2010, Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association, Circulation, 122, 406, 10.1161/CIR.0b013e3181e8edf1
Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2960, 10.1016/j.jacc.2013.11.003
Havranek, 2015, Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association, Circulation, 132, 873, 10.1161/CIR.0000000000000228
2010
Margolius, 2012, Health coaching to improve hypertension treatment in a low-income, minority population, Ann Fam Med, 10, 199, 10.1370/afm.1369
Polgreen, 2015, Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control, Hypertension, 66, 1145, 10.1161/HYPERTENSIONAHA.115.06023
Brownstein, 2007, Effectiveness of community health workers in the care of people with hypertension, Am J Prev Med, 32, 435, 10.1016/j.amepre.2007.01.011
Carter, 2009, The potency of team-based care interventions for hypertension: a meta-analysis, Arch Intern Med, 169, 1748, 10.1001/archinternmed.2009.316
Clark, 2010, Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis, BMJ, 341, c3995, 10.1136/bmj.c3995
Proia, 2014, Team-based care and improved blood pressure control: a community guide systematic review, Am J Prev Med, 47, 86, 10.1016/j.amepre.2014.03.004
Santschi, 2014, Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials, J Am Heart Assoc., 3
Shaw, 2014, Effects of nurse-managed protocols in the outpatient management of adults with chronic conditions: a systematic review and meta-analysis, Ann Intern Med, 161, 113, 10.7326/M13-2567
Thomas, 2014, Check it, change it: a community-based, multifaceted intervention to improve blood pressure control, Circ Cardiovasc Qual Outcomes, 7, 828, 10.1161/CIRCOUTCOMES.114.001039
Carter, 2015, Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control, Circ Cardiovasc Qual Outcomes, 8, 235, 10.1161/CIRCOUTCOMES.114.001283
Himmelfarb, 2016, Expanding the role of nurses to improve hypertension care and control globally, Ann Glob Health, 82, 243, 10.1016/j.aogh.2016.02.003
The Guide to Community Preventive Services (The Community Guide). Cardiovascular Disease: Team-Based Care to Improve Blood Pressure Control. 2012. Available at: https://www.thecommunityguide.org/findings/cardiovascular-disease-team-based-care-improve-blood-pressure-control. Accessed June 1, 2017.
Centers for Disease Control and Prevention. Task Force recommends team-based care for improving blood pressure control. Press Release. May 15, 2012. Available at: https://www.cdc.gov/media/releases/2012/p0515_bp_control.html. Accessed September 17, 2017.
Tsuyuki, 2016, The effectiveness of pharmacist interventions on cardiovascular risk: The Multicenter Randomized Controlled RxEACH Trial, J Am Coll Cardiol, 67, 2846, 10.1016/j.jacc.2016.03.528
Brownstein, 2007, Effectiveness of community health workers in the care of people with hypertension, Am J Prev Med, 32, 435, 10.1016/j.amepre.2007.01.011
Brush, 2015, 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers, J Am Coll Cardiol, 65, 2118, 10.1016/j.jacc.2015.03.550
Patient-Centered Primary Care Collaborative. The Patient-Centered Medical Home: Integrating Comprehensive Medication Management to Optimize Patient Outcomes: Resource Guide. 2010. Available at: https://www.pcpcc.org/sites/default/files/media/medmanagement.pdf. Accessed June 15, 2017.
Dunn, 2015, The role of the clinical pharmacist in the care of patients with cardiovascular disease, J Am Coll Cardiol, 66, 2129, 10.1016/j.jacc.2015.09.025
Rakotz, 2014, A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients, Ann Fam Med, 12, 352, 10.1370/afm.1665
Borden, 2014, Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry, J Am Coll Cardiol, 64, 2196, 10.1016/j.jacc.2014.09.022
Jaffe, 2013, Improved blood pressure control associated with a large-scale hypertension program, JAMA, 310, 699, 10.1001/jama.2013.108769
Omboni, 2013, Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies, J Hypertens, 31, 455, 10.1097/HJH.0b013e32835ca8dd
Verberk, 2011, Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis, Blood Press Monit., 16, 149, 10.1097/MBP.0b013e328346e092
Agarwal, 2011, Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis, Hypertension, 57, 29, 10.1161/HYPERTENSIONAHA.110.160911
Liu, 2013, Reducing blood pressure with Internet-based interventions: a meta-analysis, Can J Cardiol, 29, 613, 10.1016/j.cjca.2013.02.007
Burke, 2015, Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association, Circulation, 132, 1157, 10.1161/CIR.0000000000000232
Li, 2013, Approaches to the prevention and management of childhood obesity: the role of social networks and the use of social media and related electronic technologies: a scientific statement from the American Heart Association, Circulation, 127, 260, 10.1161/CIR.0b013e3182756d8e
Omboni, 2015, The role of telemedicine in hypertension management: focus on blood pressure telemonitoring, Curr Hypertens Rep, 17, 535, 10.1007/s11906-015-0535-3
Svetkey, 2009, Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients, Hypertension, 54, 1226, 10.1161/HYPERTENSIONAHA.109.134874
de Lusignan, 2013, Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results, Kidney Int, 84, 609, 10.1038/ki.2013.96
Jaffe, 2013, Improved blood pressure control associated with a large-scale hypertension program, JAMA, 310, 699, 10.1001/jama.2013.108769
Performance Management and Measurement. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2011. Available at: https://www.hrsa.gov/sites/default/files/quality/toolbox/508pdfs/performancemanagementandmeasurement.pdf. Accessed October 30, 2017.
Bardach, 2013, Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial, JAMA, 310, 1051, 10.1001/jama.2013.277353
Navar-Boggan, 2013, Variability in performance measures for assessment of hypertension control, Am Heart J, 165, 823, 10.1016/j.ahj.2013.01.003
Powers, 2011, Measuring blood pressure for decision making and quality reporting: where and how many measures?, Ann Intern Med, 154, 781, 10.7326/0003-4819-154-12-201106210-00005
Bonow, 2011, ACCF/AHA methodology for the development of quality measures for cardiovascular technology: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, J Am Coll Cardiol, 58, 1517, 10.1016/j.jacc.2011.07.007
Walsh, 2006, Quality improvement strategies for hypertension management: a systematic review, Med Care, 44, 646, 10.1097/01.mlr.0000220260.30768.32
Carter, 2009, The potency of team-based care interventions for hypertension: a meta-analysis, Arch Intern Med, 169, 1748, 10.1001/archinternmed.2009.316
Glynn, 2010, Interventions used to improve control of blood pressure in patients with hypertension, Cochrane Database Syst Rev., 10.1002/14651858.CD005182.pub4
Proia, 2014, Team-based care and improved blood pressure control: a community guide systematic review, Am J Prev Med, 47, 86, 10.1016/j.amepre.2014.03.004
Anchala, 2012, The role of Decision Support System (DSS) in prevention of cardiovascular disease: a systematic review and meta-analysis, PLoS ONE, 7, 10.1371/journal.pone.0047064
Thomas, 2014, Check it, change it: a community-based, multifaceted intervention to improve blood pressure control, Circ Cardiovasc Qual Outcomes, 7, 828, 10.1161/CIRCOUTCOMES.114.001039
Jaffe, 2013, Improved blood pressure control associated with a large-scale hypertension program, JAMA, 310, 699, 10.1001/jama.2013.108769
Agarwal, 2011, Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis, Hypertension, 57, 29, 10.1161/HYPERTENSIONAHA.110.160911
Go, 2014, An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention, Hypertension, 63, 878, 10.1161/HYP.0000000000000003
Walsh, 2005
Center for Medicare and Medicaid Services. Million Hearts: Cardiovascular Disease Risk Reduction Model. 2016. Available at: https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/. Accessed October 30, 2017.
Hysong, 2012, Financial incentives and physician commitment to guideline-recommended hypertension management, Am J Manag Care, 18, e378
Petersen, 2013, Effects of individual physician-level and practice-level financial incentives on hypertension care: a randomized trial, JAMA, 310, 1042, 10.1001/jama.2013.276303
Karunaratne, 2013, The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3-5, Nephrol Dial Transplant, 28, 2107, 10.1093/ndt/gft093
Maimaris, 2013, The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review, PLoS Med, 10, 10.1371/journal.pmed.1001490
Center for Medicare and Medicaid Services. Million Hearts: Cardiovascular Disease Risk Reduction Model. 2016. Available at: https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/. Accessed October 30, 2017.
Jaffe, 2016, The Kaiser Permanente Northern California story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013), J Clin Hypertens (Greenwich), 18, 260, 10.1111/jch.12803
Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, J Am Coll Cardiol, 58, 2432, 10.1016/j.jacc.2011.10.824
Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019
2016, Standards of Medical Care in Diabetes–2016: Summary of Revisions, Diabetes Care, 39, S4